Page last updated: 2024-11-10

thiopental

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3000715
CHEMBL ID441
CHEBI ID102166
SCHEMBL ID11946652
SCHEMBL ID1611312
MeSH IDM0021364

Synonyms (90)

Synonym
AC-16029
BRD-A72603112-236-02-4
gtpl2579
4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-
DIVK1C_000993
KBIO1_000993
5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1h,5h)-dione
SPECTRUM_001786
SPECTRUM5_001692
thionembutal
thiomebumal
5-ethyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1h,5h)-dione
5-ethyl-5-(1-methylbutyl)-2-thiobarbituric acid
intraval
5-ethyl-5-(1-methylbutyl)-2-thioxo-hexahydropyrimidine-4,6-dione
thiopentobarbituric acid
pentothiobarbital
(+-)-thiopental
thiopental [ban]
barbituric acid, 5-ethyl-5-(1-methylbutyl)-2-thio-
einecs 200-984-3
thiothal
4,6,(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-
brn 0209361
tiopentale [italian]
thiopental
76-75-5
C07521
(+/-)-thiopental
thiopentobarbitone
2-thio-5-ethyl-5-sec-pentylbarbituric acid
DB00599
thiopentobarbital
5-ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione
penthiobarbital
thiopentone
KBIO2_004840
KBIO2_002272
KBIOSS_002273
KBIO2_007408
KBIO3_002803
KBIOGR_001010
SPECTRUM4_000575
SPBIO_002215
SPECTRUM2_001998
SPECTRUM3_001781
NINDS_000993
BSPBIO_003301
IDI1_000993
CHEMBL441 ,
thiopental ciii
5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
5-ethyl-2-mercapto-5-(1-methyl-butyl)-1h-pyrimidine-4,6-dione
bdbm50058058
5-ethyl-5-(pentan-2-yl)-2-thioxodihydropyrimidine-4,6(1h,5h)-dione
CHEBI:102166 ,
SCHEMBL11946652
hsdb 7791
ec 200-984-3
ji8z5m7na3 ,
5-24-09-00172 (beilstein handbook reference)
tiopentale
unii-ji8z5m7na3
FT-0603282
EPITOPE ID:116047
AKOS015901914
thiopental [vandf]
thiopental [hsdb]
thiopental [who-dd]
thiopental ciii [usp-rs]
SCHEMBL1611312
hypnostan (salt/mix)
leopental (salt/mix)
farmotal (salt/mix)
nesdonal (salt/mix)
thiopental sodium (salt/mix)
trapanal (salt/mix)
pentothal (salt/mix)
IUJDSEJGGMCXSG-UHFFFAOYSA-N
(.+/-.)-thiopental
penthiobarbital sodium (salt/mix)
5-ethyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1h,5h)-pyrimidinedione
DTXSID1023653
5-ethyl-5-(pentan-2-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
thiopental, united states pharmacopeia (usp) reference standard
thiopental, european pharmacopoeia (ep) reference standard
thiopental for system suitability, european pharmacopoeia (ep) reference standard
5-ethyl-2-mercapto-5-(pentan-2-yl)pyrimidine-4,6(1h,5h)-dione
4,6(1h,5h)-pyrimidinedione,5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-
thiopental, 1mg/ml in methanol

Research Excerpts

Overview

Thiopental sodium (TPTS) is a barbiturate general anesthetic. Its effects on hypoxia/reoxygenation (H/R)-induced injury are still unclear. Thiopental is a more suitable agent than propofol for avoiding hypotension during GA induction under remifentanil infusion.

ExcerptReferenceRelevance
"Thiopental sodium (TPTS) is a barbiturate general anesthetic, while its effects on hypoxia/reoxygenation (H/R)-induced injury are still unclear. "( Thiopental sodium attenuates hypoxia/reoxygenation-induced injury in osteoblasts by modulating AKT signaling.
Hu, CY; Li, CT; Li, GY, 2023
)
3.8
"Thiopental is a more suitable agent than propofol for avoiding hypotension during GA induction under remifentanil infusion in the middle and elderly patients."( Comparison between hemodynamic effects of propofol and thiopental during general anesthesia induction with remifentanil infusion: a double-blind, age-stratified, randomized study.
Hino, H; Kihara, Y; Matsuura, T; Mori, T; Nishikawa, K; Tsujikawa, S, 2019
)
2.2
"Thiopental is an ultra-short-acting barbiturate, used as an induction agent during general anesthesia and to manage intra cranial pressure in traumatic brain injuries. "( HPTLC method for the assay of thiopental in post-mortem blood in a fatal case of suicide.
Mohan, BM; Nagaraju, PM; Sanganalmath, PU, 2013
)
2.12
"Thiopental is a thiobarbiturate given in the case of brain injuries to reduce intracranial pressure and to manage cerebral ischemia. "( Interaction of thiopental with esomeprazole in critically ill patients.
Boulamery, A; Dumas, M; Goirand, F; Marsot, A; Milési, N; Simon, N, 2013
)
2.19
"Thiopental is a barbiturate used in traumatic brain injuries (TBIs) to reduce intracranial pressure (ICP) and to manage cerebral ischemia. "( A critical review: does thiopental continuous infusion warrant therapeutic drug monitoring in the critical care population?
Ensom, MH; Huynh, F; Mabasa, VH, 2009
)
2.1
"Thiopental is an anesthetic used for controlling high intracranial pressure (ICP) caused by brain surgery, brain trauma, and severe stroke. "( Thiopental exaggerates ischemic brain damage and neurological deficits after experimental stroke in spontaneously hypertensive rats.
Duan, WM; Duan, YF; Liu, C; Zhao, LR; Zhao, YF, 2009
)
3.24
"Thiopental is a well-known intravenous barbiturate anesthetic with important cardiac side effects. "( Thiopental inhibits function of different inward rectifying potassium channel isoforms by a similar mechanism.
Ferrer, T; López-Izquierdo, A; Ponce-Balbuena, D; Rodríguez-Menchaca, AA; Sánchez-Chapula, JA, 2010
)
3.25
"Thiopental is a cornerstone in the treatment of refractory status epilepticus and intractable intracranial hypertension. "( Falsely elevated sodium levels during thiopental treatment in the ICU: technical interference on a laboratory device with important clinical relevance.
Coenen, D; Feyen, BF; Jorens, PG; Maas, AI; Van Hoof, V; Verbrugghe, W; Wouters, K, 2013
)
2.1
"Thiopental (TPL) is a commonly used barbiturate anesthetic. "( Interaction of anesthetic supplement thiopental with human serum albumin.
Islam, B; Khan, AU; Khan, SN; Rajeswari, MR; Usmani, H, 2008
)
2.06
"Thiopental is a fast-acting central nervous system depressant and is one of the agents used for barbiturate therapy."( Nursing management for barbiturate therapy in acute head injuries.
Jankowski, K; Mirr, MP; Taylon, MA, 1983
)
0.99
"Thiopental proved to be a useful sedating agent for this application."( Effect of thiopental, saffan, and propofol anesthesia on cardiovascular parameters and bronchial smooth muscle in the rhesus monkey.
Foster, A; Pfannkuche, HJ; Zeller, W, 1996
)
1.42
"Thiopental is an ultra short-acting barbiturate which remains the standard against which other induction agents are judged; it is also indicated for the therapy of brain hypoxic-ischaemia injuries and status epilepticus. "( Pharmacodynamics and pharmacokinetics of thiopental.
Bressolle, F; Russo, H, 1998
)
2.01
"Thiopental is a racemate. "( Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane.
Cousins, MJ; Duke, CC; Edwards, SR; Mather, LE, 1999
)
2.06
"Thiopental is a racemate of equimolar R- and S-thiopental enantiomers that have different potencies in laboratory experiments. "( Microdialysis study of the blood-brain equilibration of thiopental enantiomers.
Cousins, MJ; Duke, CC; Edwards, SR; Mather, LE, 2000
)
2
"Thiopental is an anaesthetic drug that is largely used in both short-term and long-term infusion. "( Fast, simple and cost-effective determination of thiopental in human plasma by a new HPLC technique.
Bonfigli, AR; Coppa, G; Gambini, AM; Testa, I; Testa, R; Tocchini, M, 2001
)
2.01
"Thiopental is a shorter acting alternative to pentobarbital for cerebral radioprotection."( The cerebral radioprotective effect of alternative barbiturates to pentobarbital.
DeLaney, T; Oldfield, EH; Olson, JJ; Orr, K; Shelley, C, 1992
)
1
"Thiopental is a hypnotic drug that is widely used for the induction of anaesthesia. "( [Hepatic elimination of thiopental in heart surgery patients].
Brandt, C; Lange, H; Sonntag, H; Stephan, H; Zielmann, S, 1992
)
2.03
"Thiopental is an anaesthetic drug which is currently used for cerebral resuscitation. "( [Use of thiopental in man. Determination of this drug and its metabolites in plasma and urine by liquid phase chromatography and mass spectrometry].
Berthier, JC; Bobenrieth, MJ; Bory, C; Boulieu, R; Chantin, C; Cotte, J; Fraisse, D, 1986
)
2.15

Effects

Thiopental has a negative inotropic effect on cardiac excitation-contraction coupling at the cellular level. Thiopental induction has a favourable effect on seizure when compared to propofol in patients undergoing electroconvulsive therapy.

Thiopental induction has a favourable effect on seizure when compared to propofol in patients undergoing electroconvulsive therapy. Thiopental has been used for decades in the treatment of refractory intracranial hypertension in patients with traumatic head injuries.

ExcerptReferenceRelevance
"Thiopental induction has a favourable effect on seizure when compared to propofol in patients undergoing electroconvulsive therapy."( Thiopental is better than propofol for electroconvulsive therapy.
Barbini, B; Casiraghi, GM; Colombo, C; Delmonte, D; Landoni, G; Nuzzi, M; Pasin, L; Sottocorna, O; Zangrillo, A, 2018
)
3.37
"Thiopental has a direct negative inotropic effect on cardiac excitation-contraction coupling at the cellular level, which is mediated by a decrease in [Ca2+],. "( Thiopental alters contraction, intracellular Ca2+, and pH in rat ventricular myocytes.
Damron, DS; Kanaya, N; Murray, PA; Zakhary, DR, 1998
)
3.19
"Thiopental has a metabolically neutral effect on brain tissue gases and pH, even though it is known to decrease cerebral oxygen consumption. "( Thiopental and desflurane treatment for brain protection.
Ausman, JI; Charbel, FT; Edelman, G; Hoffman, WE, 1998
)
3.19
"Thiopental has a direct (spinal) depressant effect on dorsal neuronal responses to noxious stimulus, but no significant supraspinal effect."( Thiopental directly depresses lumbar dorsal horn neuronal responses to noxious mechanical stimulation in goats.
Antognini, JF; Carstens, E; Chen, XG; Piercy, M; Sudo, M; Sudo, S, 2001
)
3.2
"Thiopental has been shown to decrease the number of apoptotic cells in the kidney tissue when administered to the donor before organ transplantation, increasing the organ viability."( The effects of thiopental on cold ischemic injury in renal transplantation.
Adali, Y; Aydeğer, C; Büyük, B; Eroğlu, HA; Karakoç, E, 2023
)
1.98
"Thiopental induction has a favourable effect on seizure when compared to propofol in patients undergoing electroconvulsive therapy."( Thiopental is better than propofol for electroconvulsive therapy.
Barbini, B; Casiraghi, GM; Colombo, C; Delmonte, D; Landoni, G; Nuzzi, M; Pasin, L; Sottocorna, O; Zangrillo, A, 2018
)
3.37
"Thiopental has been reported to reduce sympathetic tone, however, it is not clear whether change in heart rate variability is associated with depth of anaesthesia. "( Effects of thiopental on bispectral index and heart rate variability.
Edanaga, M; Hirata, N; Kamada, N; Kanaya, N; Kurosawa, S; Nakayama, M; Namiki, A; Omote, K; Tsuchiya, S, 2006
)
2.17
"Thiopental has been used for decades in the treatment of refractory intracranial hypertension in patients with traumatic and nontraumatic head injuries. "( Thiopental-induced neutropenia in two patients with severe head trauma.
Frenette, AJ; Lam, S; Perreault, MM; Williamson, DR, 2007
)
3.23
"Thiopental has mild memory effects whereas fentanyl has none."( The comparative amnestic effects of midazolam, propofol, thiopental, and fentanyl at equisedative concentrations.
Feshchenko, VA; Reinsel, RA; Veselis, RA; Wroński, M, 1997
)
1.26
"Thiopental has been shown to have cerebroprotective effects."( Thiopental induced cerebral protection during ischemia in gerbils.
Guggenheimer-Furman, E; Mayevsky, A; Meilin, S; Ornstein, E; Zarchin, N, 1998
)
2.46
"Thiopental has a direct negative inotropic effect on cardiac excitation-contraction coupling at the cellular level, which is mediated by a decrease in [Ca2+],. "( Thiopental alters contraction, intracellular Ca2+, and pH in rat ventricular myocytes.
Damron, DS; Kanaya, N; Murray, PA; Zakhary, DR, 1998
)
3.19
"Thiopental has been used as a reference for pharmacokinetic and/or pharmacodynamic models in the study of rapid and short acting effect drugs."( Pharmacodynamics and pharmacokinetics of thiopental.
Bressolle, F; Russo, H, 1998
)
1.29
"Thiopental has a metabolically neutral effect on brain tissue gases and pH, even though it is known to decrease cerebral oxygen consumption. "( Thiopental and desflurane treatment for brain protection.
Ausman, JI; Charbel, FT; Edelman, G; Hoffman, WE, 1998
)
3.19
"Thiopental has been shown to protect against cerebral ischemic damage; however, it has undesirable side effects. "( Thiopental attenuates hypoxic changes of electrophysiology, biochemistry, and morphology in rat hippocampal slice CA1 pyramidal cells.
Chambers, G; Cottrell, JE; Kass, IS; Raley-Susman, KM; Wang, J; Wang, T, 1999
)
3.19
"Thiopental has hypnotic actions in the brain, but it also depresses nociceptive transmission. "( Thiopental directly depresses lumbar dorsal horn neuronal responses to noxious mechanical stimulation in goats.
Antognini, JF; Carstens, E; Chen, XG; Piercy, M; Sudo, M; Sudo, S, 2001
)
3.2
"Thiopental has a direct (spinal) depressant effect on dorsal neuronal responses to noxious stimulus, but no significant supraspinal effect."( Thiopental directly depresses lumbar dorsal horn neuronal responses to noxious mechanical stimulation in goats.
Antognini, JF; Carstens, E; Chen, XG; Piercy, M; Sudo, M; Sudo, S, 2001
)
3.2

Actions

Thiopental sodium does blunt the degree of muscle rigidity induced by high-dose fentanyl, though not as effectively as does succinylcholine. Thiopental appears to enhance ADP- and epinephrine-induced secondary platelet aggregation.

ExcerptReferenceRelevance
"Thiopental is used to suppress cerebral metabolism during temporary clip ligation of the cerebral arteries. "( Thiopental-induced burst suppression measured by the bispectral index is extended during propofol administration compared with sevoflurane.
Kim, TK; Kim, YS; Yoon, JR, 2012
)
3.26
"Thiopental did not inhibit activated NF-kappaB directly in a cell-free system."( Thiopental inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappaB through suppression of kappaB kinase activity.
Geiger, KK; Hoetzel, A; Humar, M; Loop, T; Pahl, HL; Pannen, BH; Pischke, S; Schmidt, R, 2003
)
2.48
"Thiopental produced an increase in EEG frequency and amplitude at low concentrations (15-20 micrograms/ml total plasma, approximately 10 microM unbound), which produced a loss of righting reflex. "( Thiopental uncouples hippocampal and cortical synchronized electroencephalographic activity.
Bland, BH; MacIver, MB; Mandema, JW; Stanski, DR, 1996
)
3.18
"The thiopental group had lower cerebral oxygen delivery, but not lower cerebral metabolic rate of oxygen consumption, compared with the control group, resulting in widening C(a-v)O2 during CPB."( Pharmacologic electroencephalographic suppression during cardiopulmonary bypass: a comparison of thiopental and isoflurane.
Croughwell, ND; Newman, MF; Reves, JG; Sanderson, I; Spillane, W; White, WD, 1998
)
1
"Thiopental appears to enhance ADP- and epinephrine-induced secondary platelet aggregation by increasing AA release during primary aggregation, possibly by the activation of phospholipase A2."( Thiopental enhances human platelet aggregation by increasing arachidonic acid release.
Fukuda, K; Hatano, Y; Hirakata, H; Kitamura, R; Nakamura, K; Okuda, H; Sato, M; Toda, H; Urabe, N, 2001
)
2.47
"Thiopental prevented the increase in cerebral energy state normally observed with hypothermia and resulted in a decrease in the energy state of the brain during hypothermic circulatory arrest and subsequent reperfusion."( Barbiturates impair cerebral metabolism during hypothermic circulatory arrest.
Anderson, RV; Balaban, RS; Ceckler, TL; Clark, RE; Siegman, MG; Swain, JA, 1992
)
1
"Thiopental sodium does blunt the degree of muscle rigidity induced by high-dose fentanyl, though not as effectively as does succinylcholine. "( The effects of thiopental sodium on fentanyl-induced muscle rigidity in a human model.
Silbert, BS; Vacanti, CA; Vacanti, FX,
)
1.93

Treatment

Thiopental was added for treatment of intracranial hypertension. In thiopental-treated tissue, changes in sodium and potassium caused by anoxia and by veratridine under normoxic conditions were significantly reduced. Thiopental and ketamine treatment each reduced acute paraplegia to 17% (as compared with 61% in controls)

ExcerptReferenceRelevance
"In thiopental-treated cardiomyocytes, there was a decrease in expression of the proapoptotic protein Bax, caspase-3 activation, and intracellular Ca(2+) content. "( Cardioprotection via modulation of calcium homeostasis by thiopental in hypoxia-reoxygenated neonatal rat cardiomyocytes.
Hwang, KC; Kim, HS; Park, WK, 2010
)
1.23
"Thiopental was added for treatment of intracranial hypertension."( Frequency of non-convulsive seizures and non-convulsive status epilepticus in subarachnoid hemorrhage patients in need of controlled ventilation and sedation.
Lindgren, C; Naredi, S; Nordh, E; Olivecrona, M, 2012
)
1.1
"Thiopental treatment can result in falsely elevated serum sodium. "( Falsely elevated sodium levels during thiopental treatment in the ICU: technical interference on a laboratory device with important clinical relevance.
Coenen, D; Feyen, BF; Jorens, PG; Maas, AI; Van Hoof, V; Verbrugghe, W; Wouters, K, 2013
)
2.1
"Thiopental-treated lymphocytes exhibited an overgeneration of ROS, but no change was detected in mitochondrial glutathione quantity. "( Oxidative stress and mitochondrial glutathione in human lymphocytes exposed to clinically relevant anesthetic drug concentrations.
Antonucci, A; Delogu, G; Famularo, G; Marandola, M; Moretti, S; Signore, M; Tellan, G, 2004
)
1.77
"Thiopental treatment controlled raised ICP in five cases and pentobarbital in two cases (P=0.16)."( [Comparison of the effectiveness of pentobarbital and thiopental in patients with refractory intracranial hypertension. Preliminary report of 20 patients].
Abadal, JM; Barceló, B; de la Peña, A; Homar, J; Ibáñez, J; Molina, FJ; Pérez-Bárcena, J; Sahuquillo, J, 2005
)
1.3
"In thiopental treated rats, peak PtO2 was 24 +/- 6 torr at 10 min postischemia."( Postischemic brain oxygenation with barbiturate therapy in rats.
Frinak, S; Nemoto, EM; Taylor, F, 1979
)
0.77
"In thiopental-treated tissue, changes in sodium and potassium caused by anoxia and by veratridine under normoxic conditions were significantly reduced."( The barbiturate thiopental reduces ATP levels during anoxia but improves electrophysiological recovery and ionic homeostasis in the rat hippocampal slice.
Abramowicz, AE; Chambers, G; Cottrell, JE; Kass, IS, 1992
)
1.14
"Thiopental and ketamine treatment each reduced acute paraplegia to 17% (as compared with 61% in controls) and increased delayed paraplegia from 30% in controls to 75% and 50%, respectively (p less than 0.05 for thiopental, p = 0.10 for ketamine)."( Protecting the ischemic spinal cord during aortic clamping. The influence of anesthetics and hypothermia.
Facundus, EC; Hollier, LH; Money, SR; Naslund, TC; Skenderis, BS, 1992
)
1
"Pretreatment with thiopental 0.25 mg/kg and 0.5 mg/kg after manual venous occlusion for 1 min effectively attenuated pain associated with propofol injection."( Pretreatment with thiopental for prevention of pain associated with propofol injection.
Agarwal, A; Ansari, MF; Dhiraj, S; Gupta, D; Pandey, R; Raza, M; Singh, PK; Singh, U, 2004
)
0.98

Toxicity

Thiopental is a safe and efficacious agent for sedation of infants and young children with known or suspected congenital heart disease. The ECT series was more likely to be interrupted due to cognitive adverse effects in the thiopental group.

ExcerptReferenceRelevance
"The ionic composition of the internal environment influences the toxic effect of morphine."( Experimental research of the influence of the body electrolytic composition on the toxic effect of morphine.
Fulga, I; Manu, D; Stroescu, V,
)
0.13
" Ligation was safe when, during temporary clamping, cerebral blood flow exceeded 40 ml/100 g/min, but was deemed unsafe when flow was less than 20 ml/100 g/min."( Cerebral blood flow, internal carotid artery pressure, and the EEG as a guide to the safety of carotid ligation.
Barker, J; Fitch, W; Leech, PJ; Miller, JD, 1974
)
0.25
"Rectally-administered thiopental is a safe and effective sedative drug with a duration of action tailored to performing MRI."( Sedation for children undergoing magnetic resonance imaging: efficacy and safety of rectal thiopental.
Beek, FJ; Beekman, RP; Hoorntje, TM; Kuijten, RH, 1996
)
0.83
"(1) To investigate changes in arterial oxygen saturation via pulse oximeter (SpO2) during apnea and after reinstitution of manual ventilation at SpO2 of 95% or 90% following rapid sequence induction of anesthesia in children after 2-minute preoxygenation; (2) to determine whether the setting of a safe threshold of apneic period to an SpO2 of 95% is appropriate in children during anesthetic induction; and (3) to evaluate the influences of age, body weight, and height on the time from the start of apnea to SpO2 of 95%."( Study of the safe threshold of apneic period in children during anesthesia induction.
An, G; Deng, XM; Liao, X; Luo, LK; Tong, SY; Xue, FS, 1996
)
0.29
"The safe threshold of an apneic period setting to an SpO2 of 95% was appropriate in children during anesthesia induction."( Study of the safe threshold of apneic period in children during anesthesia induction.
An, G; Deng, XM; Liao, X; Luo, LK; Tong, SY; Xue, FS, 1996
)
0.29
" The aim of this study was to compare clinical efficacy, tolerability and adverse effects of thiopental, etomidate and propofol."( [Adverse effects reported after inductive doses of the intravenous anesthetics, thiopentone, etomidate and propofol].
Adamov, A; Djordjević, B; Krivokapić, D; Loncar-Stojiljković, D; Stojiljković, MP,
)
0.35
"17 min and the overall side-effect prevalence was 2%."( Efficacy and safety of rectal thiopental sedation in outpatient echocardiographic examination of children.
Akin, R; Dündaröz, R; Gökçay, E; Lenk, MK; Okutan, V; Sarici, SU, 2000
)
0.6
"Rectally administered thiopental is a safe and efficacious agent for sedation of infants and young children with known or suspected congenital heart disease who are undergoing echocardiography in an outpatient cardiology clinic, provided that it is used in an emergency care setting considering the risk of respiratory depression even though the prevalence of this side effect is significantly low."( Efficacy and safety of rectal thiopental sedation in outpatient echocardiographic examination of children.
Akin, R; Dündaröz, R; Gökçay, E; Lenk, MK; Okutan, V; Sarici, SU, 2000
)
0.91
"Neurotoxicity is the dose-limiting side-effect of vincristine in cancer therapy."( Effect of thiopental, propofol, and etomidate on vincristine toxicity in PC12 cells.
Chen, JT; Cheng, JT; Chou, AK; Lee, TC; Lin, CR; Lin, FC; Yang, LC, 2002
)
0.72
" It is also safe and effective at the dosage studied in children undergoing MRI."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.6
"The aim of the study was to evaluate adverse events related to the use of anesthesia and anesthetic procedures associated with interventional radiology."( Adverse effects of anesthesia in interventional radiology.
Derbent, A; Memiş, A; Oran, I; Parildar, M; Uyar, M; Yurtseven, T, 2005
)
0.33
"Interventional radiological procedures seem to be safe from an anesthesiologist's point of view."( Adverse effects of anesthesia in interventional radiology.
Derbent, A; Memiş, A; Oran, I; Parildar, M; Uyar, M; Yurtseven, T, 2005
)
0.33
" Their use is frequently associated with dose-limiting adverse effects."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
" For detecting side effect liability (ataxia, sedation, impairment of voluntary motor functions), (1) the rota-rod test, (2) measurement of spontaneous motility, (3) the weight-lifting test and (4) the thiopental sleep test were used."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.32
"Therapeutic indices calculated from the results of these in vivo experiments for the clinically used muscle relaxants are in agreement with their adverse effect profiles in humans."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
"Ivermectin is considered a very safe drug; however, there are reports of toxic effects in particularly sensitive populations or due to accidental overdose."( Central and peripheral neurotoxic effects of ivermectin in rats.
Nedeljkovic, JT; Trailovic, SM, 2011
)
0.37
" None of the patients experienced serious adverse events."( Efficacy and safety of ketamine in refractory status epilepticus in children.
Cecchi, C; Guerrini, R; Ilvento, L; L'Erario, M; Mirabile, L; Pisano, T; Rosati, A, 2012
)
0.38
"In this small, open-label, unblinded series with no concurrent control group, KE appears effective and safe in treating RSE in children."( Efficacy and safety of ketamine in refractory status epilepticus in children.
Cecchi, C; Guerrini, R; Ilvento, L; L'Erario, M; Mirabile, L; Pisano, T; Rosati, A, 2012
)
0.38
" Secondary outcomes included the rate of adverse events, intensive care unit (ICU) and hospital length of stay, hospital mortality and long-term neurological outcome, assessed with the extended Glasgow outcome scale (GOS-E) at discharge and at six 6 months."( Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety.
Bellante, F; Créteur, J; Depondt, C; Gaspard, N; Legros, B; Taccone, FS, 2016
)
0.79
" The safe preparation of medications during resuscitation requires attention, time and resources, and can be a source of medication error."( Predrawn prehospital medications are microbiologically safe for up to 48 hours.
Foster, A; Garner, A; Gutierrez, CH; Kitcher, J; Soeyland, T; Vidler, S, 2018
)
0.48
"Predrawing of the eight studied medications for urgent prehospital procedures appears to be a microbiologically safe practice with syringe dwell times up to 48 hours."( Predrawn prehospital medications are microbiologically safe for up to 48 hours.
Foster, A; Garner, A; Gutierrez, CH; Kitcher, J; Soeyland, T; Vidler, S, 2018
)
0.48
"Positive neurological outcomes and no serious adverse events were observed using TNP during emergency CEA in patients with acute brain injury."( Safety of Triple Neuroprotection with Targeted Hypothermia, Controlled Induced Hypertension, and Barbiturate Infusion during Emergency Carotid Endarterectomy for Acute Stroke after Missing the 24 Hours Window Opportunity.
Abedi, AMA; Barrett, N; Clarkson, K; Dulai, M; Elsherif, M; Hynes, N; Laffey, J; Sultan, S; Tawfick, W, 2020
)
0.56
" In this retrospective study, we compared the 2 anesthetics propofol and thiopental in terms of seizure quality, cognitive adverse effects, and clinical outcome."( Differences in Cognitive Adverse Effects and Seizure Parameters Between Thiopental and Propofol Anesthesia for Electroconvulsive Therapy.
Baune, BT; Kavakbasi, E; Stoelck, A; Wagner, NM, 2023
)
1.37
" As a downside, thiopental was also associated with a greater risk of cognitive adverse effects."( Differences in Cognitive Adverse Effects and Seizure Parameters Between Thiopental and Propofol Anesthesia for Electroconvulsive Therapy.
Baune, BT; Kavakbasi, E; Stoelck, A; Wagner, NM, 2023
)
1.49

Pharmacokinetics

There was no difference in estimated thiopental effect site concentrations between dexmedetomidine and control patients. This suggests the absence of a major pharmacodynamic interaction. An extended pharmacokinetic and pharmacodynamic study in neonates is warranted.

ExcerptReferenceRelevance
" The biologic half-life in both patients was significantly longer than previously reported values."( Pharmacokinetic properties of thiopental in two patients treated for uncontrollable seizures.
Cloyd, JC; Perrier, D; Wright, BD, 1979
)
0.55
"An extension of the Bischoff-Dedrick pharmacokinetic model is presented."( Pharmacokinetic model for simultaneous determination of drug levels in organs and tissues.
Andrade, JD; Chen, CN, 1976
)
0.26
"A nonlinear pharmacokinetic model was constructed to describe the body distribution of intravenous anesthetics, using the physiological modeling approach for drug distribution kinetics."( Nonlinear pharmacokinetic model of intravenous anesthesia.
DeAngelis, RJ; Gillis, PP; Wynn, RL, 1976
)
0.26
" This biphasic concentration:response relationship was characterized with a nonparametric pharmacodynamic model."( Thiopental pharmacodynamics. I. Defining the pseudo-steady-state serum concentration-EEG effect relationship.
Bührer, M; Ebling, WF; Hung, OR; Maitre, PO; Shafer, SL; Stanski, DR, 1992
)
1.73
" Elimination half-life was extended in the sheep (251."( A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog.
Benthuysen, JA; Ebling, WF; Ilkiw, JE; McNeal, D, 1991
)
0.54
" Application of semiparametric pharmacodynamic modeling techniques enabled us to estimate equilibration rate constant (Keo) for concentrations of thiopental between arterial plasma and the effect site."( Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats.
Danhof, M; Ebling, WF; Stanski, DR, 1991
)
0.71
" The disposition of concomitantly administered thiopental and indocyanine green (ICG), a marker of intravascular space, was determined in 21 patients, aged 20-80 yr, to determine the pharmacokinetic basis of increased reactivity of the elderly to thiopental."( The relationship of age to the pharmacokinetics of early drug distribution: the concurrent disposition of thiopental and indocyanine green.
Avram, MJ; Henthorn, TK; Krejcie, TC, 1990
)
0.75
" The population pharmacokinetic analysis demonstrated that when thiopental is administered via an iv bolus injection, traditional pharmacokinetic models limit the accurate characterization of thiopental distribution phenomena."( Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.
Maitre, PO; Stanski, DR, 1990
)
0.77
"The anesthetic requirements of chronic alcoholics for induction of anesthesia with thiopental were investigated using an electroencephalographic (EEG) measure of thiopental's CNS drug effect and pharmacodynamic modeling to relate thiopental serum concentrations to drug effect."( Chronic alcohol intake does not change thiopental anesthetic requirement, pharmacokinetics, or pharmacodynamics.
Holley, FO; Maitre, PO; Stanski, DR; Swerdlow, BN, 1990
)
0.77
" No differences in the pharmacokinetic parameters characterizing distribution and elimination of thiopentone were found between the patients undergoing nonpulsatile or pulsatile perfusion."( Thiopentone pharmacokinetics during cardiopulmonary bypass with a nonpulsatile or pulsatile flow.
Heinonen, J; Hynynen, M; Näveri, E; Neuvonen, PJ; Olkkola, KT; Palojoki, R, 1989
)
0.28
" Cumulative dose response curves for vecuronium and the pharmacodynamic variables measured were similar with both anaesthetic agents."( Lack of effects of emulsified propofol ('Diprivan') on vecuronium pharmacodynamics--preliminary results in man.
Booij, LH; Crul, JF; De Grood, PM; Van Beem, HB; Van De Wetering, M; Van Egmond, J, 1985
)
0.27
"The pharmacokinetic properties of thiopental were studied in 10 asphyxiated neonates (mean +/- SE; birth weight, 3,244 +/- 212 g; gestational age, 40 +/- 1 weeks) as part of a randomized, controlled trial which tested the ability of barbiturate therapy to decrease central nervous system damage secondary to perinatal asphyxia."( Pharmacokinetics of thiopental in the asphyxiated neonate.
Garg, DC; Goldberg, RN; Weidler, DJ; Woo-Ming, RB, 1988
)
0.88
" Thiopental elimination half-life was 14."( High-dose thiopental pharmacokinetics in brain-injured children and neonates.
Billeaud, C; Brachet-Liermain, A; Demarquez, JL; Galperine, R, 1987
)
1.59
"55 l X h-1) and elimination half-life (t 1/2 (3) = 21."( [Pharmacokinetics of thiopental in women and newborn infants].
Allain, P; Bourgeonneau, MC; Cavellat, M; Monrigal, C; Premel-Cabic, A; Turcant, A, 1986
)
0.59
" The pharmacokinetic model of thiopental is a three compartment model."( [Pharmacokinetics of intravenous non-steroidal anesthetics].
Chardon, P; Kienlen, J, 1981
)
0.55
" An inhibitory sigmoid Emax pharmacodynamic model optimally characterized the relationship between thiopental concentrations and the spectral edge."( Pharmacodynamic modeling of thiopental anesthesia.
Homer, TD; Hudson, RJ; Meathe, E; Saidman, LJ; Stanski, DR, 1984
)
0.78
" The terminal elimination half-life was of 684 +/- 168 min in the alcoholics and did not differ significantly from the value found in the controls (750 +/- 212 min)."( Thiopentone pharmacokinetics in patients with chronic alcoholism.
Couderc, E; Duvaldestin, P; Ferrier, C; Haberer, JP; Henzel, D, 1984
)
0.27
" These pharmacokinetic data were compared with those from 11 adult patients previously studied at our institution."( The pharmacokinetics of thiopental in pediatric surgical patients.
Hudson, RJ; Loomis, JC; Sorbo, S, 1984
)
0.57
" Because the disposition and anesthetic potency of the isomer is unknown, its pharmacokinetic properties were determined in humans and its anesthetic potency in mice."( Pharmacokinetics and anesthetic potency of a thiopental isomer.
Burch, PG; Harapat, S; Richards, RK; Stanski, DR, 1983
)
0.53
" The elimination half-life was of 529 +/- 97 min in the controls and of 714 +/- 252 min in the patients with cirrhosis."( Thiopental pharmacokinetics in patients with cirrhosis.
Chaux, F; Duvaldestin, P; Farinotti, M; Pandele, G; Salvadori, C, 1983
)
1.71
"A physiologically based pharmacokinetic model, which is an extension of the Bischoff-Dedrick multiorgan model, was developed to described the kinetics of barbiturates (hexobarbital, phenobarbital, and thiopental) in the rat."( Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat.
Awazu, S; Hanano, M; Igari, Y; Sugiyama, Y, 1982
)
0.68
" Mean pharmacokinetic parameters obtained for thiopental in the surgical patients were as follows: initial distribution volume 13."( Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients.
Blackman, GL; Morgan, DJ; Paull, JD; Wolf, LJ, 1981
)
0.79
" Mean values of pharmacokinetic parameters (plus or minus SD) were: initial distribution volume (V1) 17."( Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section.
Blackman, GL; Morgan, DJ; Paull, JD; Wolf, LJ, 1981
)
0.53
" For all groups a significant correlation between initial drug concentration and k12 supported th hypothesis that there distribution rate constant k12 is the predominant factor in the pharmacokinetic profile of a dose of thiopentone sufficient to obtund the eyelash reflex."( Influence of age and sex on the pharmacokinetics of thiopentone.
Andreasen, F; Christensen, JH; Jansen, JA, 1981
)
0.26
"Physiologically based pharmacokinetic modeling procedures employ anatomical tissue weight, blood flow, and steady tissue/blood partition data, often obtained from different sources, to construct a system of differential equations that predict blood and tissue concentrations."( From piecewise to full physiologic pharmacokinetic modeling: applied to thiopental disposition in the rat.
Ebling, WF; Stanski, DR; Wada, DR, 1994
)
0.52
" There was no difference in estimated thiopental effect site concentrations between dexmedetomidine and control patients, suggesting the absence of a major pharmacodynamic interaction."( Dexmedetomidine decreases thiopental dose requirement and alters distribution pharmacokinetics.
Bührer, M; Lauber, R; Maitre, PO; Mappes, A; Stanski, DR, 1994
)
0.86
"The thiopental dose-sparing effect of dexmedetomidine on the electroencephalogram is not the result of a pharmacodynamic interaction but rather can be explained by a dexmedetomidine-induced decrease in thiopental distribution volume and distribution clearances."( Dexmedetomidine decreases thiopental dose requirement and alters distribution pharmacokinetics.
Bührer, M; Lauber, R; Maitre, PO; Mappes, A; Stanski, DR, 1994
)
1.15
" Dose-dependent differences in pharmacokinetic regularities of sodium thiopental in the groups compared have been revealed."( [Pharmacokinetics and pharmacodynamics of thiopental sodium in pregnant women during cesarean section].
Folomeeva, IIu; Proshina, IV; Sariev, AK; Zerdev, VP,
)
0.63
" This study validated a novel pharmacokinetic-pharmacodynamic model based on a four-compartment pharmacokinetic model and infusion quantal dose-response data."( Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
Avram, MJ; Gentry, WB; Gupta, DK; Henthorn, TK; Howard, KA; Krejcie, TC; Shanks, CA, 1994
)
0.59
" The only significant difference in the pharmacokinetic parameters was the shortened elimination half-life in patients between 1 and 3 years of age."( Pharmacokinetics of glycopyrrolate in children.
Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J; Olkkola, KT; Rautakorpi, P,
)
0.13
" The shortened elimination half-life in children between 1 and 3 years of age is of minor clinical importance."( Pharmacokinetics of glycopyrrolate in children.
Ali-Melkkilä, T; Iisalo, E; Kaila, T; Kanto, J; Olkkola, KT; Rautakorpi, P,
)
0.13
" The model incorporated data from two separate thiopental patient studies: a pharmacokinetic study with 21 males, and a pharmacodynamic study with 30 males."( A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental.
Avram, MJ; Gentry, WB; Henthorn, TK; Krejcie, TC; Shanks, CA, 1993
)
0.78
"Thiopental was administered to neurosurgical patients for cerebral protection and its pharmacokinetic parameters were determined after a single bolus of 540, 1000 or 1500 mg (3 subjects) or after multiple doses of 250 mg (5 subjects) and 500 mg (2 subjects) every two hours for up to 7 days."( Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients.
Brès, J; Duboin, MP; Roquefeuil, B; Russo, H, 1995
)
2.06
" Therefore, it is appropriate to relate pharmacodynamic effects to racemic plasma concentrations of thiopental during IV infusion of racemic thiopental."( Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental.
Crankshaw, DP; McLeish, MJ; Morgan, DJ; Nguyen, KT; Stephens, DP, 1996
)
0.83
" Simultaneous pharmacodynamic measurements included cerebral blood flow via a Doppler flowmeter on the sagittal sinus, and an index of the depth of anesthesia based on an algesimetry method."( In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration.
Grant, C; Gray, EC; Ludbrook, GL; Upton, RN, 1996
)
0.29
" However, the following main changes in N-acetylprocainamide (metabolite) pharmacokinetic parameters were found: 1) increase of the penetration rate constants between the compartments and mean residence time during propofol anesthesia 2) prolongation of the mean residence time during thiopental anesthesia 3) increase of mean residence time of N-acetylprocainamide during anesthesia with ketamine, pentobarbital or propofol."( The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite-N-acetylprocainamide.
Orszulak-Michalak, D,
)
0.31
"The influence of general anesthesia with thiopental (10 mg/kg), ketamine (4 mg/kg), propofol (10 mg/kg) or pentobarbital (20 mg/kg) on the N-acetylprocainamide (15 mg/kg) pharmacokinetic parameters was studied in rabbits."( The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part II. N-acetylprocainamide.
Orszulak-Michalak, D,
)
0.4
"3 mg/kg) pharmacokinetic parameters was studied in rabbits."( The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part III. Propranolol.
Orszulak-Michalak, D,
)
0.13
"The influence of selected general anesthetics: thiopental, propofol, ketamine and pentobarbital on the lidocaine pharmacokinetic parameters was studied in rabbits."( The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part IV. Lidocaine.
Orszulak-Michalak, D,
)
0.39
"2 mg/kg) pharmacokinetic parameters was studied in rabbits."( The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part V. Verapamil.
Orszulak-Michalak, D,
)
0.13
" Thiopental pharmacokinetic parameters in pediatric patients were compared with those determined in an adult control group with similar total doses and durations of treatment."( Pharmacokinetics of high-dose thiopental in pediatric patients with increased intracranial pressure.
Bressolle, F; Duboin, MP; Russo, H, 1997
)
1.5
"The study was unable to determine any pharmacokinetic difference of clinical significance between the R-(+)- and S-(-)-thiopentone enantiomers and concludes that minor differences in CLT and Vss could be explained by enantioselective difference found in serum protein binding."( Pharmacokinetics of thiopentone enantiomers following intravenous injection or prolonged infusion of rac-thiopentone.
Cordato, DJ; Gross, AS; Herkes, GK; Mather, LE, 1997
)
0.3
" This method has been used in therapeutic monitoring and for the determination of pharmacokinetic parameters of thiopental in patients treated with a high dose over a long time to decrease intracranial pressure."( High-performance liquid chromatographic assay for thiopental in human plasma. Application to pharmacokinetic studies.
Allaz, JL; Bressolle, F; Russo, H, 1997
)
0.76
" Plasma concentration-time data were analyzed according to a population pharmacokinetic approach with an initial group of 65 patients."( Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries.
Duboin, MP; Russo, H; Simon, N; Urien, S, 1997
)
0.56
"A physiological pharmacokinetic model for thiopental previously developed in rats was scaled to humans by substituting human values for tissue blood flows, tissue masses, and elimination clearance in place of respective rat values."( Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans.
Björkman, S; Ebling, WF; Harapat, SR; Harashima, H; Stanski, DR; Wada, DR, 1997
)
0.78
"The physiological pharmacokinetic model developed in rats predicts thiopental pharmacokinetics in humans."( Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans.
Björkman, S; Ebling, WF; Harapat, SR; Harashima, H; Stanski, DR; Wada, DR, 1997
)
0.75
"Smoking affects the pharmacodynamic and pharmacokinetic behaviour of several drugs."( Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour.
Neuvonen, PJ; Olkkola, KT; Teiriä, H; Yli-Hankala, A, 1997
)
0.3
" Blood was sampled up to 24 hr after induction to measure thiopentone plasma concentrations and to calculate pharmacokinetic parameters."( Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour.
Neuvonen, PJ; Olkkola, KT; Teiriä, H; Yli-Hankala, A, 1997
)
0.3
" Pharmacokinetic data showed no differences between smokers and non-smokers."( Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour.
Neuvonen, PJ; Olkkola, KT; Teiriä, H; Yli-Hankala, A, 1997
)
0.3
"We conclude, that cigarette smoking does not affect the pharmacodynamic or pharmacokinetic behaviour of thiopentone."( Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour.
Neuvonen, PJ; Olkkola, KT; Teiriä, H; Yli-Hankala, A, 1997
)
0.3
"The concentration-time data of 17 patients were fit by a one compartment pharmacokinetic model in which the decline of plasma concentration during infusion was due to an increase in the clearance rate of thiopental following a latency period."( Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients.
Bressolle, F; Dubboin, MP; Russo, H; Urien, S, 1997
)
0.74
"The electroencephalographic (EEG) effects of thiopentone have been used extensively in the pharmacodynamic and pharmacokinetic modelling of drug effects in the central nervous system (CNS)."( Pharmacodynamics of thiopentone: nocifensive reflex threshold changes correlate with hippocampal electroencephalography.
Archer, DP; Roth, SH, 1997
)
0.3
" The pharmacokinetic differences may be related to the differences in the sensitivity to vecuronium between genders."( The pharmacokinetics of vecuronium in male and female patients.
An, G; Liao, X; Luo, LK; Xue, FS; Zou, Q, 1998
)
0.3
" Thiopental has been used as a reference for pharmacokinetic and/or pharmacodynamic models in the study of rapid and short acting effect drugs."( Pharmacodynamics and pharmacokinetics of thiopental.
Bressolle, F; Russo, H, 1998
)
1.48
" Additional pharmacokinetic investigations are recommended to optimise pharmacological outcomes in patients with severe head injury."( Pharmacokinetic alterations after severe head injury. Clinical relevance.
Boucher, BA; Hanes, SD, 1998
)
0.3
" The pharmacokinetic differences between R- and S-thiopental, although small, were statistically significant and were influenced by the higher f(u) of R-thiopental."( Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy.
Cordato, DJ; Gross, AS; Herkes, GK; Mather, LE, 1999
)
0.88
" The use of ketamine as an anaesthetic agent in rabbits is questionable, while the use of fentanyl in pigs, methohexitone in rats and ketamine in rats and pigs is well supported by the pharmacokinetic data."( Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man.
Björkman, S; Redke, F, 2000
)
0.31
"To simulate the time course of drug effect, it is sometimes necessary to combine the pharmacodynamic parameters from an integrated pharmacodynamic-pharmacodynamic study (e."( Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
Gregg, KM; Henthorn, TK; Minto, CF; Schnider, TW; Shafer, SL, 2003
)
0.32
"The naive approach to combining separate pharmacokinetic and pharmacodynamic studies is to simply take the k(e0) from the pharmacodynamic study and apply it naively to the pharmacokinetic study of interest."( Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
Gregg, KM; Henthorn, TK; Minto, CF; Schnider, TW; Shafer, SL, 2003
)
0.32
"T(peak) is a useful pharmacodynamic parameter and can be used to link separate pharmacokinetic and pharmacodynamic studies."( Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
Gregg, KM; Henthorn, TK; Minto, CF; Schnider, TW; Shafer, SL, 2003
)
0.32
"Some limitations of traditional ("mamillary") compartmental pharmacokinetic models of anaesthetic related drugs arise from representing the blood as a central compartment."( The two-compartment recirculatory pharmacokinetic model--an introduction to recirculatory pharmacokinetic concepts.
Upton, RN, 2004
)
0.32
"The two-compartment recirculatory model is the simplest tool available for elaborating recirculatory pharmacokinetic concepts."( The two-compartment recirculatory pharmacokinetic model--an introduction to recirculatory pharmacokinetic concepts.
Upton, RN, 2004
)
0.32
"Modeling of pharmacokinetic parameters and pharmacodynamic actions requires knowledge of the arterial blood concentration."( Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
Levitt, DG, 2004
)
0.32
"A physiologically based pharmacokinetic (PBPK) model for the tissues drained by the antecubital vein (referred to as "arm") is developed."( Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
Levitt, DG, 2004
)
0.32
" Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17."( The pharmacokinetics of piritramide after prolonged administration to intensive care patients.
Bouillon, T; Groeger, P; Kietzmann, D, 2004
)
0.32
"Despite increasing terminal elimination half-life and volume of distribution at steady state (increasing drug load for a given plasma concentration), the context-sensitive half-time of piritramide after 3 days of administration is lower than predicted from bolus kinetics, making the drug a suitable candidate for intensive care unit analgesia."( The pharmacokinetics of piritramide after prolonged administration to intensive care patients.
Bouillon, T; Groeger, P; Kietzmann, D, 2004
)
0.32
" The aim of this work is to provide an overview on physiological changes and pharmacokinetic implications of obesity for the anesthesiologist."( Anesthesia in the obese patient: pharmacokinetic considerations.
Casati, A; Putzu, M, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" To develop a safe method of administration for thiopental, an extended pharmacokinetic and pharmacodynamic study in neonates is warranted."( Thiopental pharmacokinetics in newborn infants: a case report of overdose.
Fellman, V; Malmqvist, U; Norman, E; Westrin, P, 2009
)
2.05
" Pharmacokinetic parameters were computed by plotting drug concentration versus time curve on semi log scale."( Effect of intermittent hypobaric hypoxia on efficacy & clearance of drugs.
Dey, J; Kishore, K; Vij, AG, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" Substitution of thiopentone by midazolam in combination with fentanyl abolished the adverse haemodynamic response and modified the increase in plasma catecholamine concentrations."( Catecholamine response to laryngoscopy and intubation. The influence of three different drug combinations commonly used for induction of anaesthesia.
Bjerre-Jepsen, K; Chraemmer-Jørgensen, B; Hertel, S; Høilund-Carlsen, PF; Strøm, J, 1992
)
0.28
" First, propofol infusion was compared to thiopentone combined with midazolam."( Total intravenous anaesthesia for direct laryngoscopy: propofol infusion compared to thiopentone combined with midazolam and methohexitone infusion.
Clausen, TG; Halck, S; Munksgaard, A; Sonne, NM; Valentin, N, 1992
)
0.28
"Remifentanil anesthesia, combined with small-dose propofol, desflurane, or sevoflurane, enables predictably fast and smooth early recovery after ear, nose, and throat surgery."( Recovery after anesthesia with remifentanil combined with propofol, desflurane, or sevoflurane for otorhinolaryngeal surgery.
Loop, T; Priebe, HJ, 2000
)
0.31
" In children and neonates, it is commonly used alone or in combination with thiopental or propofol."( Sevoflurane in combination with propofol, not thiopental, induces a more robust neuroapoptosis than sevoflurane alone in the neonatal mouse brain.
Kimura, K; Mizoguchi, A; Sakuraba, S; Tagawa, T, 2014
)
0.89

Bioavailability

ExcerptReferenceRelevance
"The rate of absorption and plasma concentrations of lidocaine were determined in 15 supine patients under general anesthesia following either endotracheal spray of 200 mg."( Plasma concentration of lidocaine after endotracheal spray.
Brannan, MD; Chu, SS; Cohen, JL; Rah, KH,
)
0.13
" Diazepam, which produces good tranquilization, is well absorbed when given orally though absorption is influenced by other drugs given at the same time."( New drugs--boon or bane? Premedication and intravenous induction agents.
Clarke, RS, 1983
)
0.27
"Different mechanisms are involved in drug interactions, especially between anesthetics and drug administrated before and during anesthesia: liver disease, bioavailability related to the route of administration, displacement of the protein-bound of the part, etc."( [Veterinary anesthesiology, a pharmacological model (author's transl)].
Richez, P; Ruckebusch, Y, 1980
)
0.26

Dosage Studied

The effect of thiopental on the induction dose-response curve for midazolam was studied in nonpremedicated ASA physical status I and II patients. Seizure length was directly correlated with stimulus dosage and inversely correlated with patient age, prescription of anticonvulsants in the day before and β-blockers during the session.

ExcerptRelevanceReference
" The slopes of the dose-response curves for the two catecholamines and the maxima of the curves were the same."( Substitution of calorigenic effects of noradrenaline and adrenaline and differences in their inhibition by propranolol.
Cervinka, M; Janský, L; Mejsnar, J, 1976
)
0.26
" To evaluate this possibility, the authors devised a technique for determining the minimal arrhythmic dosage of epinephrine that permitted graded assessment of changes in the sensitivity of the heart to epinephrine-induced arrhythmias."( Effects of pharmacologic alterations of adrenergic mechanisms by cocaine, tropolone, aminophylline, and ketamine on epinephrine-induced arrhythmias during halothane-nitrous oxide anesthesia.
Koehntop, DE; Liao, JC; Van Bergen, FH, 1977
)
0.26
" There was no significant difference between the mothers and babies in the three meperidine dosage groups for maternal parity, maternal age, birth weight, number of forceps deliveries or duration of labour."( Double-blind comparison of the neurobehaviour of neonates following the administration of different doses of meperidine to the mother.
Bhatt, M; Hodgkinson, R; Wang, CN, 1978
)
0.26
" The duration of sleep, determined by failure of the animals to right themselves, was then used to construct dose-response curves for the two drugs in the hyperbaric environments."( Ketamine and thiopental sleep responses in guinea pigs in hyperbaric helium-oxygen.
Bailey, RC; McCracken, LE; Nicodemus, HF; Tobey, RE, 1979
)
0.63
"5 to 1 microgram/kg) than by increasing the dosage of thiopental."( The role of different components of balanced anaesthesia in tolerance to endotracheal intubation.
Aromaa, U; Tammisto, T, 1977
)
0.51
" The toxicity of peroral triftazine administered to mice and rats is the same for both dosage forms, it being somewhat higher for intraperitoneal triftazine syrup."( [Pharmacologic characteristics of triftazin syrup].
Blinkova, NF; Parin, VV; Shcherbakova, OV; Shmar'ian, MI; Tolmacheva, NS,
)
0.13
" The shapes of the anesthetic dose-response curves for both CMRO2 and cerebral blood flow (CBF) were examined by multiple measurements made at small, progressive concentration increments from 0 to 2 MAC halothane (six dogs), enflurane (six dogs), and isoflurane (six dogs), and during a constant 23 mg/kg/hr infusion of thiopental (six dogs)."( The nonlinear responses of cerebral metabolism to low concentrations of halothane, enflurane, isoflurane, and thiopental.
Michenfelder, JD; Milde, JH; Stullken, EH; Tinker, JH, 1977
)
0.64
"Intraocular pressure (IOP) measurements were made in a series of 92 male surgical patients, to assess the effects of timing and dosage of succinylcholine given after a standardized sleep dose of thiopental (3 mg."( Thiopental and succinylcholine: Action on intraocular pressure.
Bruce, DL; Joshi, C,
)
1.76
"Using isolated rat aortic strips (AS) and portal veins (PV), it was found that all of the barbiturates studied (thiopental, secobarbital, pentobarbital, amobarbital, phenobarbital, and barbital): a) inhibit development of spontaneous mechanical activity (vasomotion) in AS and PV in concentrations used to induce surgical anesthesia or concentrations used for anticonvulsive therapy; b) dose-dependent attenuate contractions induced by epinephrine and potassium (K+); c) cause non-competitive displacement of the dose-response curves of these vasoactive compounds; d) attenuate calcium (Ca++)-induced contractions of K+-depolarized AS and PV; e) rapidly relax drug-induced, as well as Ca++-induced, contractions of AS and PV."( Barbiturates and aortic and venous smooth-muscle function.
Altura, BM; Altura, BT, 1975
)
0.47
" The doses of the anasthetic agents were selected from the dose-response experiments."( Effect of lithium and rubidium on the sleeping time caused by various intravenous anaesthetics in the mouse.
Männistö, PT; Saarnivaara, L, 1976
)
0.26
"In previously untreated rats, pretreatment with enalaprilat shifted the dose-response curve for the hypotensive effect of doxazosin to the left, indicating synergism."( A study of the interaction between the hypotensive actions of doxazosin and enalaprilat in anaesthetized rats.
Marwood, JF; Stokes, GS; Tierney, G, 1992
)
0.28
" Dose-response curves were monophasic and linear over this range."( Propofol and barbiturate depression of spinal nociceptive neurotransmission.
Gibbs, LM; Jewett, BA; Kendig, JJ; Tarasiuk, A, 1992
)
0.28
" Our results suggest that it is feasible to derive robust pharmacokinetic parameters from unusual drug dosing approaches, such as employed by a computer-controlled infusion pump."( Plasma concentration clamping in the rat using a computer-controlled infusion pump.
Ebling, WF; Gustafsson, LL; Harapat, S; Osaki, E; Shafer, SL; Stanski, DR, 1992
)
0.28
" Log-probit dose-response curves for these end-points were determined 30, 60 and 90 s after induction in 96 unpremedicated ASA group I patients."( Induction dose-responses studies with propofol and thiopentone.
el-Gammal, M; Gomma, M; Naguib, M; Sari-Kouzel, A; Seraj, M, 1992
)
0.28
" Dose-response curves for thiopentone, ketamine and their combinations were determined with a probit procedure and compared with isobolographic analysis."( Anaesthetic interaction between thiopentone and ketamine.
Bradley, EL; Gesztes, T; Katz, J; Kissin, I; Roytblat, L; Rozentsveig, V, 1992
)
0.28
" Maximum depression of the first response (T1) in the train-of-four was measured, and dose-response curves were constructed."( Nitrous oxide potentiates vecuronium neuromuscular blockade in humans.
Balendran, P; Bevan, DR; Donati, F; Fiset, P, 1991
)
0.28
" The dose-response curves were determined by probit analysis."( Thiopentone-propofol hypnotic synergism in patients.
Naguib, M; Sari-Kouzel, A, 1991
)
0.28
" Our patients required a lesser dosage for abolition of eyelash reflex than the figures recommended for British population."( Minimum induction dose (MID) of thiopentone in Pakistani patients.
Bhatti, TH; Kamal, RS; Khan, FA; Rizvi, UC; Saqib, NU, 1991
)
0.28
"Inability to open eyes on command was used as an end point of anesthesia and the dose-response curves were determined using a probit procedure."( Midazolam potentiates thiopental sodium anesthetic induction in patients.
Bradley, EL; Kissin, I; Vinik, HR,
)
0.45
" However, propranolol significantly shifted the methacholine dose-response curve to the left so that methacholine (0."( Pulmonary reactivity to methacholine during beta-adrenergic blockade: propranolol versus esmolol.
Hirshman, CA; Sauder, RA; Tobias, JD, 1990
)
0.28
" Oxotremorine-induced tremor and salivation in mice were delayed after extremely high dosage of levocabastine; however, these were much less effective than those seen after diphenhydramine and ketotifen."( Central effect of the potent long-acting H1-antihistamine levocabastine.
Aoki, I; Kamei, C; Tasaka, K; Tsujimoto, S; Yoshida, T, 1990
)
0.28
" Dose-response curves for thiopentone and midazolam individually and in combination were determined using the two end-points in 300 unpremedicated patients."( Hypnotic and anaesthetic action of thiopentone and midazolam alone and in combination.
Galletly, DC; Plummer, JL; Short, TG, 1991
)
0.28
"Rectal thiopental is superior to this drug combination for pediatric sedation because it can be administered painlessly, has a more rapid onset and offset of action, and is of equal safety and efficacy at the dosage studied."( Rectal thiopental compared with intramuscular meperidine, promethazine, and chlorpromazine for pediatric sedation.
Carey, BE; Falk, JL; Malone, LC; O'Brien, JF, 1991
)
1.19
" These doses were based on the assumption that the slope of the dose-response curve during nitrous oxide-opioid anaesthesia would be approximately the same as the slope of the neuromuscular response from the first human studies with mivacurium."( Neuromuscular and cardiovascular effects of mivacurium chloride (BW B1090U) during nitrous oxide-fentanyl-thiopentone and nitrous oxide-halothane anaesthesia.
Abou-Donia, M; Choi, WW; From, RP; Pearson, KS; Sokoll, MD, 1990
)
0.28
"3 to 19 years old were studied to determine the individual dose-response curves and the maintenance requirements of alcuronium during N2O-O2-opioid anaesthesia."( Maintenance requirement of alcuronium in paediatric patients.
Brown, TC; Meretoja, OA, 1990
)
0.28
" Dose-response curves of pancuronium were parallel in all age-groups."( Dose-response characteristics of pancuronium in neonates, infants and children.
Luosto, T; Meretoja, OA, 1990
)
0.28
" In the patients in the groups II and III the hydrocortisone in the blood, taken 1 minute before induction and 3 minutes after intubation was dosed radioimmunologically."( [Hemodynamic reaction in the ultrarapid induction and protection realized with fentanyl].
Acalovschi, I; Fleşeru, M; Szabo, P; Szilagy, E,
)
0.13
" A dose-response curve demonstrated maximal effect at 50 mumol/L of thiopental sodium, with toxic effects noted at 200 mumol/L of thiopental sodium."( Barbiturates protect retinal cells from hypoxia in cell culture.
Fukuda, M; Howe, CA; Pulido, JS; Puro, DG, 1989
)
0.51
"Single dose-response curves were determined for suxamethonium in neonates, infants and children during thiopentone-fentanyl-nitrous oxide anaesthesia."( Dose-response curves for suxamethonium in neonates, infants and children.
Baker, RD; McKiernan, EP; Meakin, G; Morris, P, 1989
)
0.28
" The dosage of thiopental was adjusted incrementally until intracranial pressure, measured by extradural transducers, fell to within normal limits or adverse hemodynamic changes occurred."( Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure.
Alexander, GJ; Dawling, S; Forbes, A; Gullan, R; Keays, R; O'Grady, JG; Williams, R, 1989
)
2.07
" This revealed that only three factors were of significance for the dosage employed: age, weight and cardiac disease."( [Calculation of the amount of thiopental used in induction of anesthesia].
Anker-Møller, E; Spangsberg, N, 1989
)
0.57
" Our findings thus indicate that in the study of drug actions on the EEG of anaesthetized animals, the results obtained not only represent the interaction of the anaesthetic and the drug on the animal EEG but is also a reflection of the dosage of the anaesthetic employed."( EEG in anaesthetized rats.
Chua, ME; Sim, MK, 1989
)
0.28
"The effect of thiopental on the induction dose-response curve for midazolam was studied in nonpremedicated ASA physical status I and II patients."( Midazolam-thiopental anesthetic interaction in patients.
Bradley, EL; Fleyshman, G; Kissin, I; Tverskoy, M, 1988
)
1.04
"This study was performed to determine the potency of succinylcholine using the single-dose technique, and to test the ability of the cumulative dose technique for generating dose-response data."( Dose-response curves for succinylcholine: single versus cumulative techniques.
Bevan, DR; Donati, F; Smith, CE, 1988
)
0.27
"We were interested in determining the dose-response relationship of atracurium in children (2-10 yr) during nitrous oxide-isoflurane anesthesia (1%) and the atracurium infusion rate required to maintain about 95% neuromuscular blockade during nitrous oxide-halothane (0."( Atracurium infusion requirements in children during halothane, isoflurane, and narcotic anesthesia.
Brandom, BW; Cook, DR; Fehr, B; Lineberry, CG; Rudd, GD; Woelfel, SK, 1985
)
0.27
" Used as an induction and maintenance agent, its anaesthetic properties, dosage requirements and side-effects were compared with those of thiopentone in 40 American Society of Anesthesiologists class I and II patients scheduled for routine oesophagoscopy."( The use of propofol in a group of older patients undergoing oesophagoscopy.
Foster, PA; Steegers, PA, 1988
)
0.27
"The induction characteristics, dosage requirements, cardiovascular and respiratory effects of propofol with added lignocaine were compared with those of thiopentone and halothane inhalational induction in two groups of children aged 1-5 years and 5-10 years."( Propofol for induction of anaesthesia in children. A comparison with thiopentone and halothane inhalational induction.
Christie, G; Grant, IS; Gray, IG; Morton, NS; Wee, M, 1988
)
0.27
"5 degrees C were measured to determine a dose-response curve."( The hypoxic mouse model for screening cerebral protective agents: a re-examination.
Milde, LN, 1988
)
0.27
" Pentobarbitone 30 micrograms/ml also significantly inhibited responses to 3 X 10(-7) M of the calcium ionophore A23187, shifted the dose-response curve for ACh to the right and suppressed the maximum ACh response."( Barbiturate inhibition of endothelium-dependent dilatation of blood- and Krebs-perfused rat tail arteries.
Gerkens, JF, 1987
)
0.27
"To determine if clinical concentrations of halothane have direct relaxant effects on airway smooth muscle, the authors compared dose-response curves to histamine in the control state (thiopental) and during halothane anesthesia (1."( Mode of action of halothane on histamine-induced airway constriction in dogs with reactive airways.
Hirshman, CA; Shah, MV, 1986
)
0.46
" Dosage according to fat-free body weight did not diminish inter-individual differences in plasma concentration-time profiles."( [Thiopental levels in the plasma during induction of anesthesia].
Finsterer, U; Lueg, J; Peter, K; Roedig, G; Taeger, K; Weninger, E, 1986
)
1.18
" The course of concentration under maintenance dosage was extremely variable, mainly due to interindividual and intraindividual variations in clearance."( [Thiopental kinetics in high-dose use].
Jensen, U; Murr, R; Peter, K; Schmiedeck, P; Taeger, K, 1986
)
1.18
"Alfentanil in combination with etomidate and N2O/O2 was given to 50 patients as single dosage (0."( [Alfentanil in routine clinical use. A study of 50 patients].
Löffler, B, 1985
)
0.27
" The data also provide evidence that thiopental in sufficient dosage can reduce the clinical consequences of these events."( Neuropsychiatric complications after cardiopulmonary bypass: cerebral protection by a barbiturate.
Arlund, C; Nussmeier, NA; Slogoff, S, 1986
)
0.54
" Thiopentone dosage was based on the mean of pharmacokinetic parameter values from the literature and adjusted for each patient's lean body mass in order to rapidly achieve a predetermined plasma thiopentone concentration of 15 or 20 micrograms/ml in the period following the initial bolus dose to induce anaesthesia."( Evaluation of infusion regimens for thiopentone as a primary anaesthetic agent.
Blackman, GL; Boyd, MD; Chan, HN; Crankshaw, DP; Edwards, NE; Morgan, DJ, 1985
)
0.27
" and an infusion (150 micrograms kg-1 min-1 for 30 min and 75 micrograms kg-1 min-1 thereafter) on the pharmacodynamics and dose-response curves of atracurium and vecuronium were studied in 52 healthy (ASA I or II) patients."( Some effects of diisopropyl phenol (ICI 35 868) on the pharmacodynamics of atracurium and vecuronium in anaesthetized man.
Booij, LH; Crul, JF; Fragen, RJ; Robertson, EN; van Egmond, J, 1983
)
0.27
" These actions of barbiturates were not accompanied by changes in the apparent dissociation constant of the GABA-current dose-response curve or the reversal potential for GABA currents."( Effect of barbiturates on the GABA receptor of cat primary afferent neurones.
Higashi, H; Nishi, S, 1982
)
0.26
"Application software for economical and convenient calculation of median effective doses, confidence limits, potency ratios and slopes of quantal dose-response curves using a microcomputer is presented."( A probit analysis program for the personal computer.
Schoofs, GM; Willhite, CC, 1984
)
0.27
" Log-probit dose-response curves of the inhibitory effects of the anesthetics on the catecholamine releases induced by acetylcholine, nicotine, and muscarine were determined."( Selective actions of intravenous anesthetics on nicotinic- and muscarinic-receptor-mediated responses of the dog adrenal medulla.
Amakata, Y; Amenomori, Y; Hirano, H; Matsumoto, T; Sumikawa, K, 1983
)
0.27
" Dose-response curves for pancuronium, duration of blockade, and adequacy of relaxation for tracheal intubation did not differ between patients receiving midazolam (N = 10) or thiopental (N = 10)."( Comparison of thiopental and midazolam on the neuromuscular responses to succinylcholine or pancuronium in humans.
Cronnelly, R; Miller, RD; Morris, RB, 1983
)
0.82
" Monitoring the intracranial pressure (ICP), BP, and thereby, the cerebral perfusion pressure (CPP) gave valuable information on the patients' state and served as a guide for dosage and timing of barbiturate therapy, and facilitated supervision of adequate ventilation."( Induced barbiturate coma: methods for evaluation of patients.
Ganes, T; Lindegaard, KF; Lundar, T, 1983
)
0.27
" The total dosage of thiopentone necessary to control the convulsions is greater than that previously reported."( A case of status epilepticus. Use of thiopentone and IPPV to control otherwise refractory convulsions.
Feneck, RO, 1981
)
0.26
" Little dose-response effect was evident for any of the drugs."( Alteration of renal hemodynamics by thiopental, diazepam, and ketamine in conscious dogs.
Priano, LL, 1982
)
0.54
" This has been used in 2206 consecutive unselected inductions, in which variables considered to be likely to influence the dosage were recorded."( The 'induction' dose of thiopentone. A method of study and preliminary illustrative results.
Dundee, JW; Hassard, TH; Henshaw, J; McGowan, WA, 1982
)
0.26
" The dose-response curves of the nettle-fed tadpoles when compared with the liver-fed tadpoles were shifted to the right."( Influence of diet on the susceptibility of Xenopus laevis tadpoles to thiopentone and a membrane probe.
Haw, ME, 1981
)
0.26
" We observed a striking reduction in the size of infarction in the animals treated with thiopental at moderate and prolonged dosage levels."( The controlled delivery of thiopental and delayed cerebral revascularization.
Agdeppa, D; Dujovny, M; Lipton, SD; Mazel, M; Nelson, D; Segel, R; Yonas, H, 1981
)
0.78
" Log-probit dose-response curves for these end-points and for lethal effect were determined."( The indices of potency for intravenous anaesthetics.
Kissin, I; McGee, T; Smith, LR, 1981
)
0.26
" Although a higher dosage of Tramadol reduces significantly the supplementary barbiturate dosage per kilogram bodyweight per minute which is required, it has no effect on the incidence of reflex movements, nor does it prevent the marked intraoperative rise of diastolic blood pressure."( [The clinical usefulness of Tramadol-infusion anaesthesia (author's transl)].
Rothhammer, A; Skrobek, W; Weis, KH, 1981
)
0.26
" The results in these patients are discussed as regards thiopentone dosage and severity of trauma."( [Barbiturate infusion in severe brain trauma (preliminary report) (author's transl)].
Hamer, J; Just, OH; Weinhardt, F; Wiedemann, K, 1980
)
0.26
" This synergism varies considerably according to the different drugs, the different endpoints of anaesthesia and the differently combined dosage of both agents."( [The art of reasonable combining drugs in anesthesia].
Glass, PS, 1994
)
0.29
" The thiopental requirements were determined by titration; the midazolam requirements were determined from dose-response curves obtained with bolus injections of predetermined doses of the drug."( Subarachnoid bupivacaine blockade decreases midazolam and thiopental hypnotic requirements.
Finger, J; Kissin, I; Shagal, M; Tverskoy, M,
)
0.89
"The dose-response relationship of commercially available preparations of methohexital, pentobarbital, phenobarbital, and thiopental and their respective drug-free solutions on granulocyte function was investigated to evaluate whether suppression of neutrophil chemiluminescence is mediated by the barbiturates themselves or by their drug-free solutions."( Do barbiturates impair zymosan-induced granulocyte function?
Birkhahn, A; Buhl, R; Mirow, N; Schneider, M; Weiss, M; Wernet, P, 1994
)
0.5
"The dose-response effects of the four barbiturates on granulocyte function were tested by zymosan-induced neutrophil chemiluminescence and, in addition, in a cell-free chemiluminescence system."( Do barbiturates impair zymosan-induced granulocyte function?
Birkhahn, A; Buhl, R; Mirow, N; Schneider, M; Weiss, M; Wernet, P, 1994
)
0.29
"The dose-response relationship of four commercially available barbiturates (methohexitone, pentobarbitone, phenobarbitone and thiopentone) and of their drug-free solutions on the production of oxygen radicals by neutrophils were tested by N-formylmethionyl-leucyl-phenylalanine (FMLP)-induced granulocyte chemiluminescence and in a cell-free chemiluminescence system."( Do barbiturates and their solutions suppress FMLP-induced neutrophil chemiluminescence?
Birkhahn, A; Buhl, R; Mirow, N; Schneider, M; Weiss, M; Wernet, P, 1994
)
0.29
" The influence of infusion rate on the dose-response relationship has not been described rigorously."( Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
Avram, MJ; Gentry, WB; Gupta, DK; Henthorn, TK; Howard, KA; Krejcie, TC; Shanks, CA, 1994
)
0.59
" This study validated a novel pharmacokinetic-pharmacodynamic model based on a four-compartment pharmacokinetic model and infusion quantal dose-response data."( Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
Avram, MJ; Gentry, WB; Gupta, DK; Henthorn, TK; Howard, KA; Krejcie, TC; Shanks, CA, 1994
)
0.59
" To establish whether placental transfer of vecuronium used in the above dosage has any clinically detectable effect upon the newborn."( Vecuronium-thiopentone induction for emergency caesarean section under general anaesthesia.
Teviotdale, BM, 1993
)
0.29
"kg-1 x min-1) until the end-point was reached and construction of the dose-response curve based on bolus injections of predetermined doses of thiopental (with the use of probit analysis)."( Metoclopramide decreases thiopental hypnotic requirements.
Bradley, EL; Kissin, I; Mehta, D, 1993
)
0.79
" We were unable to identify any differences between the two groups with respect to narcotic, benzodiazepine dosage or usage of inhalational agents."( Recall of intraoperative events after general anaesthesia and cardiopulmonary bypass.
Devitt, JH; Harrington, EM; McLean, RF; Phillips, AA, 1993
)
0.29
" In the pharmacodynamic study, cumulative quantal dose-response curves for the clinical and EEG endpoints were developed from observations made during a constant-rate infusion of thiopental."( A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental.
Avram, MJ; Gentry, WB; Henthorn, TK; Krejcie, TC; Shanks, CA, 1993
)
0.71
" After a stable baseline was obtained, dose-response curves to histamine (50, 100, or 200 micrograms intravenous bolus) or hypocapnia (0% CO2 for 2 min with 100, 200, or 400 ml/min collateral flow) were constructed."( Effects of halothane, propofol, and thiopental on peripheral airway reactivity.
Lindeman, KS; Mehr, EH, 1993
)
0.56
" Using an isolated, electrically stimulated rat left atria model, contractile dose-response curves to thiopentone (200 microM, 400 microM, 600 microM, 800 microM) were shifted to the right in preparations treated with 10(-3)M dibutyryl cyclic adenosine monophosphate (cAMP) compared with atria stimulated with 10(-6) M dibutyryl cyclic isoprenaline, demonstrating that inhibition of beta-adrenergic mechanisms by thiopentone is physiologically important."( Thiopentone inhibits beta-adrenergic responses in myocardial tissue.
Mathew, BP; Thurston, TA, 1995
)
0.29
"Using an isolated, electrically stimulated rat left afrium model, the dose-response curves to the muscarinic agonist carbachol and the anesthetics ketamine and thiopental were compared under conditions of high (10(-6)M isoproterenol bath concentration) or low (10(-6)M propranolol) beta-adrenergic tone."( In vitro myocardial depression by ketamine or thiopental is dependent on the underlying beta-adrenergic tone.
Mathew, BP; Thurston, TA, 1996
)
0.75
" Methoxyflurane shifted the 5-HT dose-response curve to lower 5-HT concentrations, without significantly changing the Hill coefficient or maximum response."( Actions of general anaesthetics on 5-HT3 receptors in N1E-115 neuroblastoma cells.
Franks, NP; Jenkins, A; Lieb, WR, 1996
)
0.29
" Neuromuscular function was recorded by adductor pollicis emg and a cumulative log-probit dose-response curve of rocuronium was established."( Rocuronium in infants, children and adults during balanced anaesthesia.
Erkola, O; Juvakoski, M; Meretoja, OA; Rautoma, P; Taivainen, T, 1996
)
0.29
" Post-ischemic administration at a dosage of 2 mg."( Effects of pre- and postischemic administration of thiopental on transmitter amino acid release and histologic outcome in gerbils.
Adachi, N; Amakawa, K; Arai, T; Fujitani, T; Ikemune, K; Liu, K, 1996
)
0.55
" The quantal dose-response curves for thiopental were calculated for 70 nonpregnant women having gynecologic surgery and for 70 pregnant women of 7-13 weeks' gestation having elective abortions."( Decreased thiopental requirements in early pregnancy.
Chan, MT; Gin, T; Mainland, P; Short, TG, 1997
)
0.97
" Log dose-response curves for hypnosis and anesthesia were calculated after logit transformation."( Decreased thiopental requirements in early pregnancy.
Chan, MT; Gin, T; Mainland, P; Short, TG, 1997
)
0.7
"The anesthetic induction agents were repeated at the same dosage when cardiopulmonary bypass was instituted."( Bolus administration of eltanolone, thiopental, or etomidate does not affect systemic vascular resistance during cardiopulmonary bypass.
Jänicke, U; Martin, K; Ott, E; Tassani, P, 1997
)
0.57
"Induction of thiopental metabolism occur within therapeutic ranges, but it was not established that attainment of individual limits in dosing rate, total dose, or treatment duration occur in the process."( Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients.
Bressolle, F; Dubboin, MP; Russo, H; Urien, S, 1997
)
0.93
"To evaluate the influence of acute isovolemic hemodilution on the dose-response and time course of action of vecuronium, we studied 60 adult patients with and without hemodilution during surgery."( The influence of acute normovolemic hemodilution on the dose-response and time course of action of vecuronium.
An, G; Li, L; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ, 1998
)
0.3
" Thiopental (100 uM) increased intracellular pH and caused an upward shift in the dose-response curve to extracellular Ca2+ for shortening, with no concomitant effect on peak [Ca2+],."( Thiopental alters contraction, intracellular Ca2+, and pH in rat ventricular myocytes.
Damron, DS; Kanaya, N; Murray, PA; Zakhary, DR, 1998
)
2.65
"(1) To compare the dose-response relations of rocuronium and vecuronium in healthy adult patients anesthetized with nitrous oxide-oxygen-fentanyl-thiopental; and (2) to evaluate the time-course of action of two drugs following equipotent doses."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.5
" The dose-response relations of rocuronium and vecuronium were determined by the cumulative dose-response technique."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.3
" The cumulative dose-response curve of vecuronium was shifted to the left in a parallel fashion compared with that of rocuronium."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.3
" Three protocols were employed to examine the inhibitory effect of thiopentone: (a) concentration-dependent effect on 10(-7) M noradrenaline (NA)- or high-K+ (40 mM)-induced contractions: (b) effect on NA-induced extra-and intracellular Ca(2+)-dependent contractions and (c) effect on the dose-response curve when Ca2+ is restored to Ca(2+)-depleted rings in Ca(2+)-free 40 mM K(+)-depolarizing medium."( Vasorelaxant effect of thiopentone in isolated human epigastric arteries.
Ebeigbe, AB; Ehigiegba, AE; Olele, NE, 1998
)
0.3
" Dose-response curves for the drugs given separately and in combinations at three different dose ratios between the drugs were determined by using a probit procedure, and the 50% effective dose values were compared by using isobolographic and algebraic (fractional) analysis."( Isobolographic analysis of propofol-thiopental hypnotic interaction in surgical patients.
Bradley, EL; Kissin, I; Vinik, HR, 1999
)
0.58
" The number of epileptic seizures, the number and dosage of antiepileptic drugs (AEDs), and psychomotor development before and after anesthesia were compared."( Efficacy of five days' barbiturate anesthesia in the treatment of intractable epilepsies in children.
Rantala, H; Remes, M; Saukkonen, AL; Uhari, M, 1999
)
0.3
" For LRP and DF, premedication was associated with significant, non-parallel increases in the slope of the thiopental dose-response curves, resulting in marked potency ratio changes from ED50 to ED95 (LRP +31%, DF +29%)."( Midazolam premedication and thiopental induction of anaesthesia: interactions at multiple end-points.
Bissonnette, B; Decosterd, LA; Despland, PA; Ravussin, PA; Wilder-Smith, OH, 1999
)
0.81
" In the REM groups, the dosage of PRO (75 microg."( Recovery after anesthesia with remifentanil combined with propofol, desflurane, or sevoflurane for otorhinolaryngeal surgery.
Loop, T; Priebe, HJ, 2000
)
0.31
"The study was undertaken to evaluate the effectiveness of large (divided) thiopentone dosage on the peripheral haemodynamic response to laryngoscopy and intubation."( Second dose thiopentone attenuates the haemodynamic response to laryngoscopy and intubation.
Ebegue, AF, 2001
)
0.31
" We review the use of thiopentone for this purpose, in particular the evidence for efficacy, mechanism of action and optimal dosage and timing of administration."( Cerebral protection with thiopentone during combined carotid endarterectomy and clipping of intracranial aneurysm.
Kien, ND; McConkey, PP, 2002
)
0.31
"The dosage of thiopental was 50 mg per kg for infants under 6 months of age, 35 mg per kg between six and 12 months, and 25 mg per kg for older children."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.96
" It is also safe and effective at the dosage studied in children undergoing MRI."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.6
" The family survey and dosage of porphyric compounds in the sickness-bearing patient's family members allow to reveal certain asymptomatic forms of the heriditary acute porphyria, it is caused by certain products used in neuropsychiatry, in aneasthesic or in certain circunstances, such as, the infection or the trauma."( [Fatal postoperative crisis in acute hereditary porphyria].
Abbes, I; Affes, N; Ben Amar, M; Beyrouti, MI; Frikha, MF; Mseddi, MA; Zouari, R, 2002
)
0.31
" Group 1--bolus dosing of a 20% solution of gamma oxy-oil acid (GOOA), 75-100 mg/kg; group 2--bolus dosing of a 1% solution of thiopental sodium (5-7 mg/kg); and group 3--micro-flow introduction of dormycum (0."( [Central hemodynamics during therapeutic sedation in children under artificial pulmonary ventilation].
Nikitin, VV; Ostreĭkov, IF; Petrova, ZhI; Shtatnov, MK; Tarasov, SV,
)
0.34
" Dosage below 25 mg."( A barbiturate antidote. Use of methylethyl-glutarmide in barbiturate intoxication and in terminating barbiturate anesthesia.
MARMER, MJ, 1959
)
0.24
" Dosing of the analgesics and sedatives was based on a neonatal sedation score for ventilated infants."( Endogenous distress in ventilated full-term newborns with acute respiratory failure.
Aretz, S; Licht, C; Roth, B, 2004
)
0.32
" Dose-response experiments were also performed in vitro with single agents."( In vivo and in vitro effects of different anaesthetics on platelet function.
Ardito, G; Bruno, MF; Ciabattoni, G; Crocchiolo, R; de Cristofaro, R; Dordoni, PL; Frassanito, L; Landolfi, R; Proietti, R; Rocca, B, 2004
)
0.32
"Forty-eight subjects were included in a within-subject logistic dose-response model analysis."( Enhanced visual memory effect for negative versus positive emotional content is potentiated at sub-anaesthetic concentrations of thiopental.
Feshchenko, VA; Pryor, KO; Reinsel, RA; Veselis, RA, 2004
)
0.53
" A condition for antidote effect of the Krebs intermediate was sufficiently high dosage (5 mmol/kg), further dose increase made no odds."( Intermediates of Krebs cycle correct the depression of the whole body oxygen consumption and lethal cooling in barbiturate poisoning in rat.
Ivnitsky, JJ; Malakhovsky, VN; Rejniuk, VL; Schäfer, TV, 2004
)
0.32
" Pharmacokinetic parameters of muscle relaxants are minimally affected by obesity, and their dosage is based on ideal rather than TBW."( Anesthesia in the obese patient: pharmacokinetic considerations.
Casati, A; Putzu, M, 2005
)
0.33
" Statistically significant multivariate predictors of hypotension 0-10 min after anesthetic induction included: ASA III-V, baseline MAP <70 mm Hg, age > or =50 yr, the use of propofol for induction of anesthesia, and increasing induction dosage of fentanyl."( Predictors of hypotension after induction of general anesthesia.
Baez, B; Bernstein, A; Bodian, CA; Hossain, S; Krol, M; Patel, P; Reich, DL, 2005
)
0.33
" Hypnotic and lethal dose-response curves were constructed for thiopenthal alone and in combination with fentanyl (0."( Interaction between thiopental and fentanyl in mice is different between hypnotic and lethal doses.
Ben-Abraham, R; Ben-Shlomo, I; Hadash, O; Katz, Y, 2005
)
0.65
" The dosage and pharmacokinetics of the analgesic should also be taken into consideration because an insufficient analgesia leads to a faster flattening of the depth of anaesthesia."( [Depth of anaesthesia during intubation: comparison between propofol and thiopentone].
Bajorat, J; Beck, CE; Hofmockel, R; Janda, M; Pohl, B, 2006
)
0.33
" Reduction of the barbiturate dosage resulted in clinical and subclinical partial seizures appearing repetitively in clusters."( Acute encephalitis with refractory, repetitive partial seizures: case reports of this unusual post-encephalitic epilepsy.
Inoue, T; Maegaki, Y; Nanba, Y; Ogura, K; Ohno, K; Okamoto, R; Saito, Y; Takahashi, Y; Togawa, M, 2007
)
0.34
" We studied the effect of melatonin premedication on the propofol and thiopental dose-response curves for abolition of responses to verbal commands and eyelash stimulation."( The effects of melatonin premedication on propofol and thiopental induction dose-response curves: a prospective, randomized, double-blind study.
Al-Ayyaf, HA; Alharby, SW; Alshaer, AA; Fadin, A; Mansour, Eel-D; Moniem, MA; Naguib, M; Samarkandi, AH, 2006
)
0.81
" Dose-response curves were determined by probit analysis."( The effects of melatonin premedication on propofol and thiopental induction dose-response curves: a prospective, randomized, double-blind study.
Al-Ayyaf, HA; Alharby, SW; Alshaer, AA; Fadin, A; Mansour, Eel-D; Moniem, MA; Naguib, M; Samarkandi, AH, 2006
)
0.58
" Execution outcomes from North Carolina and California together with interspecies dosage scaling of thiopental effects suggest that in the current practice of lethal injection, thiopental might not be fatal and might be insufficient to induce surgical anesthesia for the duration of the execution."( Lethal injection for execution: chemical asphyxiation?
Koniaris, LG; López-Muñoz, F; Lubarsky, DA; Sheldon, J; Waterman, L; Weisman, R; Zimmers, TA, 2007
)
0.56
"Although BIS became considerably appreciated, growing experience and repeated education had no impact on drug dosing and BIS levels."( Bispectral index monitoring: appreciated but does not affect drug dosing and hypnotic levels.
Brudin, L; Lindholm, ML; Sandin, RH, 2008
)
0.35
" Monitoring the AAI facilitates the titration of thiopental and propofol dosing during anesthetic induction."( [Influence of inhaled nitrous oxide on the induction doses of propofol and thiopental assessed by auditory evoked potentials].
Bellolio, PC; Domínguez, VC, 2007
)
0.82
" However, SEP monitoring can be done with sevoflurane inhalation, but the dosage should be adjusted due to interindividual variability."( Somatosensory evoked potentials by median nerve stimulation in children during thiopental/sevoflurane anesthesia and the additive effects of ketoprofen and fentanyl.
Hyvärinen, A; Kokki, H; Nieminen, K; Partanen, J; Westerén-Punnonen, S; Yppärilä-Wolters, H, 2008
)
0.57
" Most of the debate has surrounded the dosing and procedures used in lethal injection and whether the drug combinations and measures for administering the drugs truly produce a timely, pain-free, and fail-safe death."( Issues surrounding lethal injection as a means of capital punishment.
Fink, JL; Romanelli, F; Whisman, T, 2008
)
0.35
" Algorithm-based charge dosing was used."( Comparison of propofol and thiopental as anesthetic agents for electroconvulsive therapy: a randomized, blinded comparison of seizure duration, stimulus charge, clinical effect, and cognitive side effects.
Báez, A; Bauer, J; Bolwig, T; Dam, H; Hageman, I; Jørgensen, MB; Olsen, NV; Roed, J, 2009
)
0.65
" These results show that thiopental concentrations are variable in neonates and there is a high risk of dosage error as no specific paediatric formulation is available."( Thiopental pharmacokinetics in newborn infants: a case report of overdose.
Fellman, V; Malmqvist, U; Norman, E; Westrin, P, 2009
)
2.1
" The onset depends on the dosage used."( Rapid sequence intubation: a review of recent evidences.
Di Filippo, A; Gonnelli, C, 2009
)
0.35
"The aim of the present study was to determine the dosage of remifentanil that must be added to thiopental 5 mg kg(-1) to provide excellent intubating conditions in 95% of patients."( What is the optimal remifentanil dosage for providing excellent intubating conditions when coadministered with thiopental? A prospective randomized dose-response study.
Allaouchiche, B; Boselli, E; Bouvet, L; Chassard, D; Rousson, D; Stoian, A, 2010
)
0.79
"The dosage of remifentanil providing excellent intubating conditions in 95% of patients when coadministered with thiopental 5 mg kg(-1) in healthy premedicated female patients undergoing elective surgery was more than 7 microg kg(-1)."( What is the optimal remifentanil dosage for providing excellent intubating conditions when coadministered with thiopental? A prospective randomized dose-response study.
Allaouchiche, B; Boselli, E; Bouvet, L; Chassard, D; Rousson, D; Stoian, A, 2010
)
0.78
" During the first 4 h after birth the dose needs to be adjusted for maternal dosage as well as for the weight of the infant."( Placental transfer and pharmacokinetics of thiopentone in newborn infants.
Fellman, V; Norman, E; Westrin, P, 2010
)
0.36
" A 1 mL/kg dosage of a 300 mg/mL solution of iohexol was administered at a rate of 3 mL/s during GFR measurement."( Evaluation of the effects of thiopental, propofol, and etomidate on glomerular filtration rate measured by the use of dynamic computed tomography in dogs.
Chang, D; Chang, J; Choi, M; Jung, J; Kim, S; Lee, H; Lee, I; Lee, Y; Yoon, J, 2011
)
0.66
" We analysed the number of sessions until completion of ECT treatment (used as a surrogate parameter for outcome), psychopathology as assessed by pre- and post-ECT Mini-Mental State Examination (MMSE) and Hamilton Rating Scale for Depression (HAM-D) scores as well as ECT and seizure parameters (stimulation dose, seizure duration and concordance, urapidil dosage for post-seizure blood pressure management)."( Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study.
Hoyer, C; Kammerer-Ciernioch, J; Kranaster, L; Sartorius, A, 2011
)
0.37
" Algorithm-based charge dosing was used."( Effect of propofol versus sodium thiopental on electroconvulsive therapy in major depressive disorder: a randomized double-blind controlled clinical trial.
Balkç, A; Deniz, S; Erdem, M; Özdemir, B; Öznur, T; Purtuloğlu, T; Ünlü, G, 2013
)
0.67
" The potential of antipyrine phenotyping for individualisation of anesthetics' dosing is discussed."( [Phenotyping by total oxidative hepatic capacity in patients undergoing laparoscopic cholecystectomy: two categories of patients and duration of post-anesthesia rehabilitation].
Chuenkova, EA; Ziganshina, LE, 2013
)
0.39
"(1) BPC 157 own effect on thiopental anaesthesia: BPC 157 (10 ng/kg and 10 μg/kg) caused a significant antagonism of general anaesthesia produced by thiopental with a parallel shift of the dose-response curve to the right."( BPC 157 antagonized the general anaesthetic potency of thiopental and reduced prolongation of anaesthesia induced by L-NAME/thiopental combination.
Balenovic, I; Cilic, AZ; Cilic, M; Djuzel, V; Drmic, D; Holjevac, JK; Kokot, A; Murselovic, T; Radic, B; Seiwerth, S; Sikiric, P; Stambolija, V; Suran, J; Uzun, S; Vlainic, J; Zemba, M, 2015
)
0.96
"Opioids are integral part of anesthesia induction, but information on optimal dosing is limited."( Dose requirements of alfentanil to eliminate autonomic responses during rapid-sequence induction with thiopental 4 mg/kg and rocuronium 0.6 mg/kg.
Abou-Arab, MH; Heier, T; Rostrup, M, 2016
)
0.65
"159 mg/kg, can be useful to adjust the dosage of IV oxycodone for maintain stable BP during induction of general anesthesia."( Optimal dose of intravenous oxycodone for attenuating hemodynamic changes after endotracheal intubation in healthy patients: A randomized controlled trial.
Baek, CW; Jung, YH; Kang, H; Lee, OH; Lee, SH; Park, YH; Shin, HY; Woo, YC, 2017
)
0.46
"A retrospective cohort study utilizing a case-based analysis comparing number of re-stimulations, length of seizures, number of ECTs per series and stimulation dosage before and after introducing a new treatment regimen."( Delaying initiation of electroconvulsive treatment after administration of the anaesthetic agent and muscle relaxant reduces the necessity of re-stimulation.
Asztalos, M; Hessellund, KB; Licht, RW; Matzen, P; Nielsen, RE; Sartorius, A, 2018
)
0.48
" No effect of treatment regimen on duration of seizures as measured clinically or by EEG, on number of treatments per series or on stimulation dosage was observed."( Delaying initiation of electroconvulsive treatment after administration of the anaesthetic agent and muscle relaxant reduces the necessity of re-stimulation.
Asztalos, M; Hessellund, KB; Licht, RW; Matzen, P; Nielsen, RE; Sartorius, A, 2018
)
0.48
"Analysis of the results of pharmacological phenotyping using antipyrine test prior to providing anesthesia for laparoscopic cholecystectomy showed that trimeperidine (promedol) dosing with allowance for the total oxidative capacity of liver and the patient mass allows the periods of post-anesthetic rehabilitation to be controlled."( POST-ANESTHETIC REHABILITATION PERIODS AND ANESTHESIA DOSAGE FOR LAPAROSCOPIC CHOLECYSTECTOMY: RELATIONSHIP TO THE TOTAL OXIDATIVE CAPACITY OF LIVER.
Chuenkova, EA; Simushkin, SV; Ziganshina, LE, 2016
)
0.43
" Sedation was maintained with further intravenous thiopental dosing as needed."( Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study.
Lehtinen, M; Löyttyniemi, E; Manner, T; Saari, TI; Scheinin, M; Uusalo, P, 2019
)
0.77
"Premedication with IN dexmedetomidine (3 μg/kg) was associated with markedly reduced thiopental dosage needed for efficient procedural sedation for pediatric MRI."( Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study.
Lehtinen, M; Löyttyniemi, E; Manner, T; Saari, TI; Scheinin, M; Uusalo, P, 2019
)
0.74
" This variable warrants consideration when interpreting ictal EEGs, which often informs subsequent dosing decisions."( The anaesthetic-ECT time interval with thiopentone-Impact on seizure quality.
Bull, M; Galvez, V; Hadzi-Pavlovic, D; Harper, S; Leyden, J; Loo, C; Martin, D; Nikolin, S; Taylor, R; Wark, H, 2019
)
0.51
" Seizure length was directly correlated with stimulus dosage and inversely correlated with the session number, patient age, prescription of anticonvulsants in the day before and β-blockers during the session, and the thiopental dose."( Factors Associated With Seizure Adequacy Along the Course of Electroconvulsive Therapy.
Chiavaro da Fonseca, R; Magalhães, PVS; Martini, M; Patusco, LM; Tedeschi, EA; Zahler, S, 2021
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
intravenous anaestheticnull
anticonvulsantA drug used to prevent seizures or reduce their severity.
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID485281
USP1 protein, partialHomo sapiens (human)Potency100.00000.031637.5844354.8130AID504865
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency44.66840.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.35480.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.505710.0000AID71999
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.497310.0000AID71999
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.498810.0000AID71999
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.504610.0000AID71999
Sodium- and chloride-dependent GABA transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00132.22068.3000AID71999
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Sodium- and chloride-dependent GABA transporter 2Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00321.79008.3000AID71999
Sodium- and chloride-dependent GABA transporter 3Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00321.54318.3000AID71999
Sodium- and chloride-dependent betaine transporterRattus norvegicus (Norway rat)IC50 (µMol)29.50000.00321.54318.3000AID71999
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.506510.0000AID71999
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.505710.0000AID71999
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)2,000.00000.00051.33138.0000AID346665
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)29.50000.00010.507510.0000AID71999
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)POT30.00000.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)POT30.00000.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)POT30.00000.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)POT30.00000.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)POT30.00000.10500.64402.0000AID52291
Gamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)POT30.00000.10500.64402.0000AID52291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (73)

Assay IDTitleYearJournalArticle
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID52291Concentration required to potentiate GABA-evoked currents in voltage-clamped bovine chromaffin cells by 300%1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID1209339Ratio of drug level in brain to plasma in Sprague-Dawley rat at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID210604Therapeutic index by the ratio between LD50 to HD501997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID346665Inhibition of rat FAAH2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1145608Drug absorption in anesthetized rat colon at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1209399AUC(0 to 7 hrs) in Sprague-Dawley rat cerebrospinal fluid at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1209383AUC(0 to 7 hrs) in Sprague-Dawley rat plasma at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1209423AUC(0 to infinity) in Sprague-Dawley rat brain at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1209407AUC(0 to infinity) in Sprague-Dawley rat cerebrospinal fluid at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1209347Ratio of drug level in cerebrospinal fluid to unbound plasma concentration in Sprague-Dawley rat at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID119225Effect on interval between loss of righting reflex and return to righting reflex (sleep duration) was measured at a dose twice that of hypnotic dose.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID1130940Retention index of the compound by HPLC method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1209355Ratio of unbound brain concentration to drug level in cerebrospinal fluid in Sprague-Dawley rat at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1209391AUC(0 to infinity) in Sprague-Dawley rat plasma at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1209415AUC(0 to 7 hrs) in Sprague-Dawley rat brain at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID26578pKa value of the compound; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1209363Ratio of unbound drug level in brain to plasma in Sprague-Dawley rat at 0.2 mg/kg, sc by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID167610Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID114282Hypnotic dose was determined by observing loss of righting reflex for a minimum period of 30 sec in 50% of treated mice after i.v. administration.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1130943Octanol-water partition coefficient, log P of nonionized form of compound1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID71999The concentration required to inhibit 50% of binding of [35S]TBPS to Gamma-aminobutyric acid A receptor to rat whole brain membranes.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors.
AID169098Negative log of molar concentration (-log C) required to produce 50% inhibition of oxygen (oxygen uptake) on rat brain respiration in vitro; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1130944Hypnotic activity in rabbit1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID38915Negative log of molar concentration (-log ED50) required to reduce cell division by 50% in Arbacia egg; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1209592Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1145610Dissociation constant, pKa of the compound at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346705Rat Kv3.4 (Voltage-gated potassium channels)2005Journal of pharmacological sciences, Oct, Volume: 99, Issue:2
Inhibitory effect of thiopental on ultra-rapid delayed rectifier K+ current in H9c2 cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,021)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904037 (67.05)18.7374
1990's1078 (17.90)18.2507
2000's569 (9.45)29.6817
2010's287 (4.77)24.3611
2020's50 (0.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.62 (24.57)
Research Supply Index8.96 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index129.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials916 (13.31%)5.53%
Reviews158 (2.30%)6.00%
Case Studies439 (6.38%)4.05%
Observational8 (0.12%)0.25%
Other5,360 (77.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (21)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT02377778]Phase 4180 participants (Actual)Interventional2009-01-31Completed
Ketamine Versus Low Dose Thiopental for Rapid-sequence Induction of Anesthesia in Patients With Septic Shock [NCT03104140]Phase 326 participants (Actual)Interventional2017-04-12Completed
A Comparative Study of Depth of Anesthesia Monitored by BIS Values in Two Anesthesia Techniques [NCT01140100]Phase 282 participants (Actual)InterventionalCompleted
The Effects of Remifentanil and Remifentanil-Alfentanil Administration on Emergence Agitation After Brief Ophthalmic Surgery in Children [NCT02486926]102 participants (Actual)Interventional2012-11-30Completed
Thiopental Versus Propofol During Magnetic Resonance Imagining in Children [NCT01318044]Phase 1/Phase 2100 participants (Anticipated)Interventional2011-01-31Recruiting
Gamma-Aminobutyric Acid (GABA) Mechanisms Underlying the Vulnerability to Alcohol Dependence [NCT00611767]73 participants (Actual)Interventional2005-11-30Completed
SUPER-refractory Status Epilepticus After Cardiac Arrest: a Multicenter, Retrospective, Cohort Study of Dual Anti-glutamate Therapy With Ketamine and Perampanel [NCT05756621]80 participants (Anticipated)Observational2022-01-15Recruiting
Understanding How Anaesthesia Affects ECT Outcomes [NCT03105245]Phase 354 participants (Actual)Interventional2017-03-15Completed
Onset Time of Thiopental Versus Propofol in the Elderly [NCT00965107]Phase 478 participants (Anticipated)Interventional2009-09-30Completed
Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes [NCT00504894]Phase 460 participants (Actual)Interventional2007-03-31Terminated(stopped due to One study drug (thiopental) became commercially unavailable)
Effects of Sedation on Spinal Anesthesia-induced Maternal Hypotension in Preoperatively Anxious Parturients Undergoing Urgent Category-1 Cesarean Section: A Historical Cohort Study [NCT02732197]102 participants (Actual)Observational2014-08-31Completed
phase2 Study of Prevention of Complications of Strabismus Surgery [NCT00478907]Phase 2300 participants (Actual)Interventional2004-03-31Completed
The Influence of Induction Agents of General Anesthesia (Etomidate and Thiopental) on Serum Cortisol Concentration in Morbidly Obese Patients. A Randomized Controlled Trial. [NCT01930019]82 participants (Actual)Interventional2009-06-30Completed
The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone. [NCT01495949]Phase 492 participants (Actual)Interventional2011-12-31Completed
The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of Postoperative Nausea and Vomiting in the Women Patients Undergoing Thyroidectomy [NCT02809378]Phase 4150 participants (Actual)Interventional2016-06-30Completed
Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension. [NCT00622570]Phase 344 participants (Actual)Interventional2002-05-31Terminated(stopped due to Slowly recruitment rate. Intermediate analysis)
Comparison of Thiopental and Propofol as Anaesteticum During ECT [NCT00379886]100 participants (Anticipated)Interventional2003-01-31Recruiting
Effect of Affective Content on Drug Induced Amnesia of Episodic Memory [NCT00142493]Phase 179 participants (Actual)Interventional2004-09-30Completed
The Effect of Intravenous Anesthetics on Fear Learning and Memory [NCT00767767]67 participants (Actual)Interventional2008-10-31Completed
TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation [NCT02056236]172 participants (Actual)Interventional2014-04-30Completed
A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus [NCT00265616]Phase 323 participants (Actual)Interventional2006-05-31Terminated(stopped due to Insufficient recruitment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00265616 (6) [back to overview]Refractory Status Epilepticus Controlled With First Course of Study Drug
NCT00265616 (6) [back to overview]Clinical Outcome at Day 21
NCT00265616 (6) [back to overview]Intubation Time in Survivors
NCT00265616 (6) [back to overview]Patients With Hypotension Requiring Specific Treatment
NCT00265616 (6) [back to overview]Patients With Infectious Complications Requiring Specific Treatment
NCT00265616 (6) [back to overview]Patients With Propofol Infusion Syndrome
NCT00504894 (2) [back to overview]Blood-oxygen-level-dependent Significant Activation Cluster
NCT00504894 (2) [back to overview]Blood-oxygen-level-dependent Significant Activation Cluster for Positive Sequential Memory
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 170 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 230 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 45 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 80 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - Baseline
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant- 110 Minutes
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Clinician Rated - 110 Minutes
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Clinician Rated - 15 Minutes
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Clinician Rated - 80 Minutes
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Clinician Rated - Baseline
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Patient Rated - 110 Minutes
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Patient Rated - 15 Minutes
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Patient Rated - 80 Minutes
NCT00611767 (78) [back to overview]Clinician Administered Dissociative Symptoms Scale - Patient Rated - Baseline
NCT00611767 (78) [back to overview]Hopkins Verbal Learning Task (HVLT) - Delayed Recall
NCT00611767 (78) [back to overview]Hopkins Verbal Learning Task (HVLT) - Total Recall
NCT00611767 (78) [back to overview]Number of Drinks Felt Consumed - 110 Minutes
NCT00611767 (78) [back to overview]Number of Drinks Felt Consumed - 15 Minutes
NCT00611767 (78) [back to overview]Number of Drinks Felt Consumed - 170 Minutes
NCT00611767 (78) [back to overview]Number of Drinks Felt Consumed - 230 Minutes
NCT00611767 (78) [back to overview]Number of Drinks Felt Consumed - 45 Minutes
NCT00611767 (78) [back to overview]Number of Drinks Felt Consumed - 80 Minutes
NCT00611767 (78) [back to overview]Number of Drinks Felt Consumed at Baseline
NCT00611767 (78) [back to overview]Pegboard Task - 15 Minutes (Dominant Hand)
NCT00611767 (78) [back to overview]Pegboard Task - 15 Minutes (Non-Dominant Hand)
NCT00611767 (78) [back to overview]Pegboard Task - Baseline (Dominant Hand)
NCT00611767 (78) [back to overview]Pegboard Task - Baseline (Non-Dominant Hand)
NCT00611767 (78) [back to overview]Verbal Fluency
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Anxious - 110 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Anxious - 15 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Anxious - 170 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Anxious - 230 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Anxious - 45 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Anxious - 80 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Anxious - Baseline
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Buzzed - 110 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Buzzed - 15 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Buzzed - 170 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Buzzed - 230 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Buzzed - 45 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Buzzed - 80 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Buzzed - Baseline
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Depressed - 110 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Depressed - 15 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Depressed - 170 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Depressed - 230 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Depressed - 45 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Depressed - 80 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Depressed - Baseline
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Drowsy - 110 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Drowsy - 15 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Drowsy - 170 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Drowsy - 230 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Drowsy - 45 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Drowsy - 80 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - Drowsy - Baseline
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - High - 110 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - High - 15 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 110 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - High - 230 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - High - 45 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - High - 80 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - High - Baseline
NCT00611767 (78) [back to overview]Visual Analog Scales of Similarity to Alcohol - 110 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales of Similarity to Alcohol - 15 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales of Similarity to Alcohol - 170 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales of Similarity to Alcohol - 230 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales of Similarity to Alcohol - 45 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales (VAS) - High - 170 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales of Similarity to Alcohol - Baseline
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 15 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 170 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 230 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 45 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 80 Minutes
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative Baseline
NCT00611767 (78) [back to overview]Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 15 Minutes
NCT00611767 (78) [back to overview]Visual Analog Scales of Similarity to Alcohol - 80 Minutes
NCT00767767 (1) [back to overview]GSR Trial 1

Refractory Status Epilepticus Controlled With First Course of Study Drug

Control of status epilepticus refractory to benzodiazepines and a first antiepileptic drug after administration of the study drug; dichotomous assessment (yes/no) (NCT00265616)
Timeframe: after return of continuous EEG activity (typically after 36 hours - 5 days)

Interventionparticipants (Number)
Propofol6
Thiopental/Pentobarbital2

[back to top]

Clinical Outcome at Day 21

Return to baseline clinical conditions (i.e.: no new handicap, no death) (NCT00265616)
Timeframe: 21 days

Interventionparticipants (Number)
Propofol5
Thiopental/Pentobarbital3

[back to top]

Intubation Time in Survivors

(NCT00265616)
Timeframe: Up to 3 months

Interventiondays (Median)
Propofol4
Thiopental/Pentobarbital13.5

[back to top]

Patients With Hypotension Requiring Specific Treatment

(NCT00265616)
Timeframe: 10 days

Interventionparticipants (Number)
Propofol7
Thiopental/Pentobarbital5

[back to top]

Patients With Infectious Complications Requiring Specific Treatment

(NCT00265616)
Timeframe: 10 days

Interventionparticipants (Number)
Propofol7
Thiopental/Pentobarbital6

[back to top]

Patients With Propofol Infusion Syndrome

Propofol infusion syndrome (PRIS) is a severe metabolic alteration with elevation of lactate, CK, and triglycerides. (NCT00265616)
Timeframe: 10 days

Interventionparticipants (Number)
Propofol1
Thiopental/Pentobarbital0

[back to top]

Blood-oxygen-level-dependent Significant Activation Cluster

Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was < 0.001, and then the P value was < 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was < 0.001, and then the P value was < 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported. (NCT00504894)
Timeframe: for 90 minutes after the drug/placebo was commenced

,,
InterventionBOLD significantly activated clusters (Number)
Right AmygdalaLeft AmygdalaRight HippocampusLeft HippocampusRight Parahippocampal CortexLeft Parahippocampal Cortex
Placebo111100
Propofol110000
Thiopental110100

[back to top]

Blood-oxygen-level-dependent Significant Activation Cluster for Positive Sequential Memory

Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was < 0.001, and then the P value was < 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was < 0.001, and then the P value was < 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported. (NCT00504894)
Timeframe: for 90 minutes after the drug/placebo was commenced

,,
InterventionBOLD significantly activated clusters (Number)
Right AmygdalaLeft AmygdalaRight HippocampusLeft HippocampusRight Parahippocampal CortexLeft Parahippocampal Cortex
Placebo010100
Propofol000000
Thiopental001001

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 170 Minutes

Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.981.85
Family History Positive1.391.65

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 230 Minutes

Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism11.72
Family History Positive2.302.04

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 45 Minutes

Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.331.13
Family History Positive2.701.57

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 80 Minutes

Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.371.5
Family History Positive1.781.35

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - Baseline

Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.862.74
Family History Positive1.221.91

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant- 110 Minutes

Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.121.44
Family History Positive1.521.91

[back to top]

Clinician Administered Dissociative Symptoms Scale - Clinician Rated - 110 Minutes

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 20 extreme dissociative) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.210
Family History Positive0.170

[back to top]

Clinician Administered Dissociative Symptoms Scale - Clinician Rated - 15 Minutes

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 20 extreme dissociative) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.430.02
Family History Positive1.040

[back to top]

Clinician Administered Dissociative Symptoms Scale - Clinician Rated - 80 Minutes

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 20 extreme dissociative) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.680
Family History Positive0.350.09

[back to top]

Clinician Administered Dissociative Symptoms Scale - Clinician Rated - Baseline

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 20 extreme dissociative) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020
Family History Positive00

[back to top]

Clinician Administered Dissociative Symptoms Scale - Patient Rated - 110 Minutes

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 84 extreme dissociative) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.430
Family History Positive0.220

[back to top]

Clinician Administered Dissociative Symptoms Scale - Patient Rated - 15 Minutes

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 84 extreme dissociative) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.570.02
Family History Positive1.740.04

[back to top]

Clinician Administered Dissociative Symptoms Scale - Patient Rated - 80 Minutes

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 84 extreme dissociative) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.730
Family History Positive0.830

[back to top]

Clinician Administered Dissociative Symptoms Scale - Patient Rated - Baseline

Clinician Administered Dissociative Symptoms Scale (CADSS) is a patient and Clinician rated measurement of dissociative states induced by thiopental (0 not at all dissociative - 84 extreme dissociative) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Hopkins Verbal Learning Task (HVLT) - Delayed Recall

Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function with word recall at 30 minutes) (0 no words recalled - 12 all words recalled) (NCT00611767)
Timeframe: 45 minutes

,
Interventionwords recalled (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism8.2910.44
Family History Positive8.7410.04

[back to top]

Hopkins Verbal Learning Task (HVLT) - Total Recall

Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function based on word recall. (0 = no words recalled - 36 = all words recalled) (NCT00611767)
Timeframe: 15 minutes

,
Interventionwords recalled (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism25.8829.02
Family History Positive26.9629.35

[back to top]

Number of Drinks Felt Consumed - 110 Minutes

The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00611767)
Timeframe: 110 minutes

,
Interventionnumber of drinks felt consumed (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.350.04
Family History Positive0.220

[back to top]

Number of Drinks Felt Consumed - 15 Minutes

The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00611767)
Timeframe: 15 minutes

,
Interventionnumber of drinks felt consumed (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism3.280.11
Family History Positive3.220.17

[back to top]

Number of Drinks Felt Consumed - 170 Minutes

The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00611767)
Timeframe: 170 minutes

,
Interventionnumber of drinks felt consumed (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00.02
Family History Positive00

[back to top]

Number of Drinks Felt Consumed - 230 Minutes

The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00611767)
Timeframe: 230 minutes

,
Interventionnumber of drinks felt consumed (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Number of Drinks Felt Consumed - 45 Minutes

The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00611767)
Timeframe: 45 minutes

,
Interventionnumber of drinks felt consumed (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism30.03
Family History Positive2.910.04

[back to top]

Number of Drinks Felt Consumed - 80 Minutes

The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00611767)
Timeframe: 80 minutes

,
Interventionnumber of drinks felt consumed (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.140.04
Family History Positive0.960

[back to top]

Number of Drinks Felt Consumed at Baseline

The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00611767)
Timeframe: Baseline

,
Interventionnumber of drinks felt consumed (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Pegboard Task - 15 Minutes (Dominant Hand)

The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds (NCT00611767)
Timeframe: 15 minutes

,
Interventionseconds (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism84.5665.11
Family History Positive82.0469.61

[back to top]

Pegboard Task - 15 Minutes (Non-Dominant Hand)

The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds. (NCT00611767)
Timeframe: 15 minutes

,
Interventionseconds (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism91.1971.13
Family History Positive87.0975.48

[back to top]

Pegboard Task - Baseline (Dominant Hand)

The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds (NCT00611767)
Timeframe: Baseline

,
Interventionseconds (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism58.4957.37
Family History Positive60.5760.78

[back to top]

Pegboard Task - Baseline (Non-Dominant Hand)

The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds. (NCT00611767)
Timeframe: Baseline

,
Interventionseconds (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism64.1962.98
Family History Positive66.5269.83

[back to top]

Verbal Fluency

"Verbal Fluency Task: requires subjects to generate as many words as possible beginning with a single letter (e.g., H) during a one-minute interval. (total words in one-minute interval)" (NCT00611767)
Timeframe: 15 minutes

,
Interventionnumber of words (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism13.4714.35
Family History Positive13.9614.04

[back to top]

Visual Analog Scales (VAS) - Anxious - 110 Minutes

visual analog scale (VAS): self-report scale used to measure anxiety (0 not at all anxious - 7 extremely anxious) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00.02
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - Anxious - 15 Minutes

visual analog scale (VAS): self-report scale used to measure anxiety (0 not at all anxious - 7 extremely anxious) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.210
Family History Positive0.220.04

[back to top]

Visual Analog Scales (VAS) - Anxious - 170 Minutes

visual analog scale (VAS): self-report scale used to measure anxiety (0 not at all anxious - 7 extremely anxious) (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00.04
Family History Positive00.04

[back to top]

Visual Analog Scales (VAS) - Anxious - 230 Minutes

visual analog scale (VAS): self-report scale used to measure anxiety (0 not at all anxious - 7 extremely anxious) (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive0.040.04

[back to top]

Visual Analog Scales (VAS) - Anxious - 45 Minutes

visual analog scale (VAS): self-report scale used to measure anxiety (0 not at all anxious - 7 extremely anxious) (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.070
Family History Positive0.130

[back to top]

Visual Analog Scales (VAS) - Anxious - 80 Minutes

visual analog scale (VAS): self-report scale used to measure anxiety (0 not at all anxious - 7 extremely anxious) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.050
Family History Positive00.04

[back to top]

Visual Analog Scales (VAS) - Anxious - Baseline

visual analog scale (VAS): self-report scale used to measure anxiety (0 not at all anxious - 7 extremely anxious) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.120.09
Family History Positive0.130.13

[back to top]

Visual Analog Scales (VAS) - Buzzed - 110 Minutes

visual analog scale (VAS): self-report scale used to measure buzzed (0 not at all buzzed - 7 extremely buzzed) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020.02
Family History Positive0.130

[back to top]

Visual Analog Scales (VAS) - Buzzed - 15 Minutes

visual analog scale (VAS): self-report scale used to measure buzzed (0 not at all buzzed - 7 extremely buzzed) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.070
Family History Positive1.650.04

[back to top]

Visual Analog Scales (VAS) - Buzzed - 170 Minutes

visual analog scale (VAS): self-report scale used to measure buzzed (0 not at all buzzed - 7 extremely buzzed) (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - Buzzed - 230 Minutes

visual analog scale (VAS): self-report scale used to measure buzzed (0 not at all buzzed - 7 extremely buzzed) (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - Buzzed - 45 Minutes

visual analog scale (VAS): self-report scale used to measure buzzed (0 not at all buzzed - 7 extremely buzzed) (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.740
Family History Positive1.260.04

[back to top]

Visual Analog Scales (VAS) - Buzzed - 80 Minutes

"visual analog scale (VAS): self-report scale used to measure buzzed (0 not at all buzzed - 7 extremely buzzed)~." (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.210.04
Family History Positive0.520

[back to top]

Visual Analog Scales (VAS) - Buzzed - Baseline

visual analog scale (VAS): self-report scale used to measure buzzed (0 not at all buzzed - 7 extremely buzzed) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - Depressed - 110 Minutes

visual analog scale (VAS): self-report scale used to measure depressed (0 not at all depressed - 7 extremely depressed) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - Depressed - 15 Minutes

visual analog scale (VAS): self-report scale used to measure depressed (0 not at all depressed - 7 extremely depressed) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020.04
Family History Positive0.130

[back to top]

Visual Analog Scales (VAS) - Depressed - 170 Minutes

visual analog scale (VAS): self-report scale used to measure depressed (0 not at all depressed - 7 extremely depressed) (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - Depressed - 230 Minutes

visual analog scale (VAS): self-report scale used to measure depressed (0 not at all depressed - 7 extremely depressed) (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - Depressed - 45 Minutes

visual analog scale (VAS): self-report scale used to measure depressed (0 not at all depressed - 7 extremely depressed) (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020.04
Family History Positive0.090

[back to top]

Visual Analog Scales (VAS) - Depressed - 80 Minutes

visual analog scale (VAS): self-report scale used to measure depressed (0 not at all depressed - 7 extremely depressed) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020
Family History Positive0.040

[back to top]

Visual Analog Scales (VAS) - Depressed - Baseline

visual analog scale (VAS): self-report scale used to measure depressed (0 not at all depressed - 7 extremely depressed) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.070
Family History Positive0.040

[back to top]

Visual Analog Scales (VAS) - Drowsy - 110 Minutes

visual analog scale (VAS): self-report scale used to measure drowsy (0 not at all drowsy - 7 extremely drowsy) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.190.13
Family History Positive1.130.30

[back to top]

Visual Analog Scales (VAS) - Drowsy - 15 Minutes

visual analog scale (VAS): self-report scale used to measure drowsy (0 not at all drowsy - 7 extremely drowsy) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.860.39
Family History Positive1.740.35

[back to top]

Visual Analog Scales (VAS) - Drowsy - 170 Minutes

visual analog scale (VAS): self-report scale used to measure drowsy (0 not at all drowsy - 7 extremely drowsy) (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.380.15
Family History Positive0.260.22

[back to top]

Visual Analog Scales (VAS) - Drowsy - 230 Minutes

visual analog scale (VAS): self-report scale used to measure drowsy (0 not at all drowsy - 7 extremely drowsy) (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.310.11
Family History Positive0.130.17

[back to top]

Visual Analog Scales (VAS) - Drowsy - 45 Minutes

"visual analog scale (VAS): self-report scale used to measure drowsy (0 not at all drowsy - 7 extremely drowsy)~." (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism3.020.44
Family History Positive2.740.39

[back to top]

Visual Analog Scales (VAS) - Drowsy - 80 Minutes

visual analog scale (VAS): self-report scale used to measure drowsy (0 not at all drowsy - 7 extremely drowsy) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.140.20
Family History Positive1.480.35

[back to top]

Visual Analog Scales (VAS) - Drowsy - Baseline

visual analog scale (VAS): self-report scale used to measure drowsy (0 not at all drowsy - 7 extremely drowsy) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.610.22
Family History Positive0.520.48

[back to top]

Visual Analog Scales (VAS) - High - 110 Minutes

visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.140
Family History Positive0.130

[back to top]

Visual Analog Scales (VAS) - High - 15 Minutes

visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.350
Family History Positive1.740

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 110 Minutes

Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.370.63
Family History Positive1.610.78

[back to top]

Visual Analog Scales (VAS) - High - 230 Minutes

visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales (VAS) - High - 45 Minutes

visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.690
Family History Positive1.260

[back to top]

Visual Analog Scales (VAS) - High - 80 Minutes

visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.400.02
Family History Positive0.610

[back to top]

Visual Analog Scales (VAS) - High - Baseline

visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales of Similarity to Alcohol - 110 Minutes

Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00611767)
Timeframe: 110 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.350.11
Family History Positive0.220

[back to top]

Visual Analog Scales of Similarity to Alcohol - 15 Minutes

Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism3.230.04
Family History Positive2.350.17

[back to top]

Visual Analog Scales of Similarity to Alcohol - 170 Minutes

Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.020.02
Family History Positive00

[back to top]

Visual Analog Scales of Similarity to Alcohol - 230 Minutes

Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales of Similarity to Alcohol - 45 Minutes

Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism2.910.04
Family History Positive1.870.04

[back to top]

Visual Analog Scales (VAS) - High - 170 Minutes

visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Visual Analog Scales of Similarity to Alcohol - Baseline

Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism00
Family History Positive00

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 15 Minutes

Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism16.071.41
Family History Positive6.742.04

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 170 Minutes

Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) (NCT00611767)
Timeframe: 170 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.830.26
Family History Positive0.520.44

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 230 Minutes

Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) (NCT00611767)
Timeframe: 230 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.450.15
Family History Positive0.220.26

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 45 Minutes

Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) (NCT00611767)
Timeframe: 45 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism15.831.70
Family History Positive9.301.17

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 80 Minutes

Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism7.980.94
Family History Positive3.480.74

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative Baseline

Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) (NCT00611767)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism1.491.20
Family History Positive0.480.44

[back to top]

Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 15 Minutes

Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) (NCT00611767)
Timeframe: 15 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism5.261.5
Family History Positive3.871.87

[back to top]

Visual Analog Scales of Similarity to Alcohol - 80 Minutes

Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00611767)
Timeframe: 80 minutes

,
Interventionunits on a scale (Mean)
ThiopentalPlacebo
Family History Negative for Alcoholism0.840.04
Family History Positive0.500

[back to top]

GSR Trial 1

Galvanic skin repose (GSR) to the first habituation trial (yes/no). Coding: Yes (0) and No (1) (NCT00767767)
Timeframe: First Trial, for up to 1 day

Interventionunits on a scale (Mean)
Placebos.62
Propofol 0.45mcg/mL.55
Propofol 0.9mcg/mL.55
Thiopental 1.5mcg/mL.67
Thiopental 3mcg/mL0

[back to top]